The therapeutic potential of small molecules p53-MDM protein-protein interaction inhibitors by Nunes, Rute Cláudia Correia Sacadura
UNIVERSIDADE DE LISBOA 
FACULDADE DE FARMÁCIA 
 
 
 
 
 
 
 
 
 
 
 
 
The therapeutic potential of small molecules 
p53-MDM protein-protein interaction inhibitors 
 
 
 
 
 
Rute Cláudia Correia Sacadura Nunes 
 
 
 
Dissertação orientada pela Doutora Maria Manuel Duque Vieira Marques dos 
Santos e coorientada pela Doutora Joana São José Dias Amaral 
 
 
 
 
Mestrado em Ciências Biofarmacêuticas 
 
 
2016 
2 
UNIVERSIDADE DE LISBOA 
FACULDADE DE FARMÁCIA 
 
 
 
 
 
 
 
 
 
 
 
 
The therapeutic potential of small molecules 
p53-MDM protein-protein interaction inhibitors 
 
 
 
 
 
Rute Cláudia Correia Sacadura Nunes 
 
 
 
Dissertação orientada pela Doutora Maria Manuel Duque Vieira Marques dos 
Santos e coorientada pela Doutora Joana São José Dias Amaral 
 
 
 
 
Mestrado em Ciências Biofarmacêuticas 
 
 
2016 
 
3 
 
RESUMO 
Ao longo dos anos, vários estudos científicos têm comprovado a importância da proteína 
supressora de tumor p53 na homeostase celular. Esta proteína encontra-se inativada em 
aproximadamente 50% dos tumores humanos, quer seja por mutação ou por deleção do seu 
gene. Por outro lado, a inativação da p53 por inibição reversível é frequentemente observada 
nos tumores que expressam a forma selvagem da proteína. Esta inativação pode resultar da 
sobre-expressão dos seus reguladores negativos, tais como a proteínas MDM2 e MDMX, 
conduzindo a patologias oncogénicas caracterizadas principalmente pela expressão da p53 do 
tipo selvagem. Vários estudos têm demonstrado que a interação da p53 com as MDM’s 
envolve três aminoácidos hidrofóbicos (Phe19, Trp23 e Leu26) da proteína p53. Além disso, 
sabe-se que a reativação da p53 é facilitada pela inibição destas interações. Nos últimos anos, 
várias famílias de compostos têm sido concebidas e desenvolvidas como moduladoras da 
atividade da p53. No entanto, o objetivo de desenvolver uma terapia anti-tumoural baseada na 
inibição das interações p53-MDM’s, e consequentemente na reativação da p53, encontra-se 
ainda no início, com apenas alguns candidatos em ensaios clínicos. Deste modo, torna-se 
premente a descoberta e desenvolvimento de inibidores mais potentes e seletivos para a 
interação entre a p53 e os seus reguladores negativos. 
Nos últimos anos, o nosso grupo de investigação tem vindo a investigar o potencial de 
várias famílias de spirooxindoles com anéis de cinco membros para o tratamento do cancro. 
Trabalhos anteriormente desenvolvidos pelo grupo, mostraram que as spiropirazolinas e 
spiroisoxazolina oxindoles apresentam propriedades anticancerígenas in vitro. O anel spiro 
encontrado nestes compostos funciona como uma estrutura heterocíclica rígida, a partir da 
qual podem ser projetados os três grupos lipofílicos que mimetizam a Phe19, Trp23 e Leu26 da 
p53. Estudos mais detalhados sobre o mecanismo de ação das spiroisoxazolina oxindoles 
mostraram que estes compostos inibem a interação p53-MDM2. No entanto, estes compostos 
apenas induziram moderada atividade anti-proliferativa (IC50 cerca de 35 μM) para a linha 
celular de cancro colo-retal humano HCT-116. Estudos de química computacional indicaram 
que esta moderada atividade resulta provavelmente da orientação espacial do oxindole nestes 
compostos não permitir que mimetizasse o resíduo Trp23 da p53, fundamental para ocorrer a 
ligação à proteína MDM2. Em particular, os estudos de docking molecular mostraram que o 
oxindole é projetado para a cavidade que seria ocupada pela Phe19 da proteína p53, enquanto 
os grupos aromáticos ligados ao anel de isoxazolina são projetados para as cavidades Trp23 e 
Leu26 da p53. A substituição do átomo de oxigénio do anel de isoxazolina por um grupo N-Ar, 
poderia permitir não só a inclusão de mais um substituinte no anel de 5 membros, como uma 
reorientação dos substituintes do anel de 5 membros de forma a ocuparem as cavidades da 
MDM2 a que se ligam os aminoácidos da p53.  
Por esse motivo, foi desenvolvida uma família de spiropirazolina oxindoles que foi testada 
nas linhas celulares de cancro da mama humano, MCF-7 e MDA-MB-231. Os compostos 
mais ativos apresentaram um valor de IC50 cerca de 7 μM. Adicionalmente, estes compostos 
apresentaram seletividade para a linha celular MDA-MB-231 e não foram tóxicos em células 
não tumorais Hek-293T. Nesta dissertação, otimizou-se esta família de compostos 
(spiropirazolina oxindoles) e avaliou-se em mais detalhe os seus efeitos biológicos. As 
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spiropirazolina oxindoles foram obtidas através de uma reação de cicloadição 1,3-dipolar 
entre 2-indolinonas e nitrilo iminas (formadas in situ a partir de cloretos de hidrazonoílo). 
Esta nova biblioteca de compostos foi caracterizada e posteriormente avaliada quanto ao seu 
potencial anti-proliferativo in vitro, utilizando as linhas celulares humanas de cancro colo-
retal HCT-116 e cancro da mama MCF-7 e MDA-MB-231, e glioma de murino GL-261. Para 
a linha de cancro colo-retal os compostos apresentaram atividades entre os 11-13 µM, e para 
as linhas de cancro da mama MCF-7 e MDA-MB-231 apresentaram atividades de 7-12 µM e 
6-11 µM, respetivamente. No caso da linha celular de glioma de murino, apenas um composto 
apresentou valores de atividade anti-proliferativa na mesma gama de valores com um IC50 de 
19 µM. De salientar, a inclusão de um grupo N-Ar aumentou para mais do dobro a capacidade 
anti-proliferativa em HCT-116 p53(+/+), quando é feita uma comparação direta entre os 
compostos equivalentes de spiroisoxazolina oxindoles.  
Com o intuito de avaliar o potencial citotóxico dos compostos em células saudáveis, foi 
realizado o ensaio de viabilidade celular em fibroblastos de colon humano normal e em 
culturas primárias de astroglia de murino. Como resultado, dois compostos (2e e 2m) 
pertencentes à família spiropirazolina oxindoles não apresentaram citotoxicidade nas células 
saudáveis, apesar de serem citotóxicos nas linhas celulares de cancro. O mesmo não se 
verificou para o composto 2q, para o qual foi observada citotoxicidade tanto em células 
normais como cancerígenas. Os compostos não citotóxicos em células normais foram então 
avaliados quanto à sua capacidade de indução de apoptose e paragem do ciclo celular na linha 
celular HCT-116. Os resultados demonstraram que estes compostos induzem tanto a morte 
por apoptose como a paragem do ciclo celular na fase G0/G1, estando ambos os fenómenos 
dependentes do tempo de exposição ou concentração de composto utilizada. 
Com a finalidade de confirmar a capacidade desta família de compostos para induzir a 
morte celular, foram ainda avaliados os níveis de libertação da enzima citoplasmática lactato 
desidrogenase (LDH) indicativos do grau de rutura da membrana celular e, por conseguinte, 
de morte. Os resultados obtidos corroboraram o ensaio de apoptose, confirmando assim a 
capacidade de indução de morte dependente da concentração. As spiropirazolina oxindoles 
apresentaram ainda a capacidade de aumentar os níveis de expressão da p53 e induzir a 
inibição da MDM2, através da diminuição dos seus níveis de expressão proteica. 
Adicionalmente, a aptidão destes compostos para inibir a interação p53-MDM2 foi observada 
através do ensaio de complementação de fluorescência bimolecular (BiFC), e foi ainda 
verificada uma boa estabilidade em PBS (pH 7.4). Por último, foi observado um efeito 
sinergético entre um agente quimioterapêutico amplamente utilizado na clínica e um dos 
compostos em estudos. 
As spiropirazolina oxindoles foram também avaliadas quanto à capacidade de induzir 
apoptose e paragem do ciclo celular na linha de glioma de murino GL-261. No entanto, os 
resultados obtidos não demonstraram qualquer evidência de indução de apoptose ou paragem 
do ciclo celular nestas células, indicando que estes compostos não têm potencial terapêutico 
neste tipo de tumores. 
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No âmbito desta tese foi também estudado em mais detalhe o mecanismo de ação de três 
spirotriazolina oxindoles previamente desenvolvidas no grupo como potenciais agentes 
anticancerígenos. Resultados obtidos anteriormente, tinham demonstrado que esta família 
apresentava boa seletividade para as linhas de cancro da mama MCF-7 e MDA-MB-231, sem 
apresentar citotoxicidade na linha não-tumoral Hek-293T. Observou-se ainda a capacidade 
destes compostos para inibir a interação p53-MDM2, ativar as caspases-3 e -7 e, 
consequentemente, induzir apoptose. Por último, uma boa estabilidade em plasma já tinha 
sido observada para os compostos em estudo.  
De forma a estudar o eventual mecanismo de ação desta família de compostos como 
potenciais agentes anticancerígenos, na presente dissertação, testaram-se os compostos mais 
promissores de spirotriazolina oxindoles em células da linha de cancro colo-retal HCT-116, 
tendo-se verificado que estes compostos induzem apoptose e clivagem da PARP, assim como 
a paragem do ciclo celular na fase G0/G1, sendo esta dependente do tempo de exposição ou 
da concentração de composto utilizada. Adicionalmente, avaliou-se a capacidade destes 
compostos para ativar a p53 e diminuir os níveis de expressão de MDM2, indicando uma 
potencial inibição da interação p53-MDM2. A indução de apoptose e paragem do ciclo celular 
foi também avaliada na linha celular de cancro da mama MDA-MB-231. Contudo, os 
resultados obtidos não demonstraram qualquer indução de apoptose após 72 horas de 
exposição das células ao composto. Porém, às 48 horas de exposição das células ao composto 
foi possível verificar a ativação das caspases-3 e -7 e paragem do ciclo celular na fase G2/M. 
Por último, os compostos mais promissores de spirotriazolina oxindoles foram testados em 
fibroblastos de colon humano normal, não se tendo verificado citotoxicidade para as 
concentrações testadas. 
Em suma, nesta dissertação demonstrou-se o potencial de cinco compostos (2e, 2m, 7f, 7h 
e 7z) pertencentes a duas famílias de spirooxindoles, contendo anéis heterocíclicos de 5 
membros, como agentes anticancerígenos e inibidores da interação proteína-proteína p53-
MDM2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: Spirooxindoles, cancro, p53, MDM's. 
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ABSTRACT 
Over the years, several scientific studies have been proving the importance of the p53 
tumour suppressor protein, in cellular homeostasis. This protein is found inactivated in 
approximately 50% of human cancers, by mutation or deletion of its gene. Moreover, the 
inactivation of p53 by reversible inhibition is frequently observed in various human cancers, 
especially in those expressing wild type p53. This inactivation results from overexpression of 
its negative regulators such as MDM2 and MDMX, leading to oncogenic pathologies, mostly 
characterized by expression of a p53 wild type form. Several studies have shown that p53 
interaction with its negative regulators involves three main hydrophobic amino acids (Phe19, 
Trp23 and Leu26) in the p53 protein. Moreover, it is known that p53 reactivation is facilitated 
by inhibition of its negative regulators. In recent few years, several families of compounds 
were designed and developed as modulators of p53. However, the development of a p53 
reactivating cancer therapy through inhibition of p53–MDM´s interaction is still at the 
beginning, with only a few candidates entering clinical trials. Therefore, the discovery of 
more powerful and selective p53–MDM´s interaction inhibitors are still an unmet need. 
The work developed in this master thesis aimed at developing new anticancer agents 
containing a spirooxindole scaffold having a pyrazoline ring. The spiro ring works as the rigid 
heterocyclic scaffold, from which the three lipophilic groups can be projected to mimic the 
p53 amino acids. The first goal included the development and optimization of a potential new 
anticancer agent by 1,3-dipolar cycloaddition reaction, complemented with biological activity 
studies, such as evaluation of cell death and cell cycle progression, and analysis of p53-
MDM2 interaction. In addition, studies of combination therapy using the newly synthetized 
molecules and a chemotherapeutic agent commonly used in the clinic, were also performed 
and finally, the stability of the compound in a saline solution was assessed. The second main 
goal of this thesis was to understand the effect of changing the carbon atom by a nitrogen 
atom in position 4´ of the pyrazoline ring. 
The results presented here reveal the potential anticancer activity of the new molecules, as 
shown by the ability to induce apoptosis and cell cycle arrest, inhibit the interaction between 
p53 and MDM2, while presenting good stability in PBS and no cytotoxic effects in normal 
human cells. Furthermore, a synergistic effect with the chemotherapeutic agent was observed. 
The change of the carbon atom for a nitrogen atom in position 4´ (pyrazoline ring replaced 
by a tryazoline ring) led to a new family of small molecules that has the ability to increase the 
expression of p53, thus leading to apoptosis and cell cycle arrest. In addition, these 
compounds were not cytotoxic in human normal cells. 
 
 
 
 
 
 
 
Key-words: Spirooxindoles, cancer, p53, MDM´s. 
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ABBREVIATIONS 
⁰C    Celsius degrees 
% (w/v)   Weight/volume percentage 
5-Fu   5-Fluorouracil 
7-AAD   7-Aminoactinomycin 
Abs   Absorbance 
Apaf-1   Apoptosis protease activating factor-1 
ATP   Adenosine-5'-triphosphate 
Bax   Bcl-2-associated X protein  
Bcl-2   B-cell lymphoma protein 2 
BiFC   Bimolecular fluorescence complementation assay 
BSA   Bovine serum albumin  
C    Carbon atom 
Ca2+   Calcium 
Caspase   Cysteine-aspartic protease  
CCD-18Co  Human normal colon fibroblasts cell line 
CDI   Coefficient Drug Interaction 
CH2Cl2   Dichloromethane  
CO2   Carbon dioxide 
CRC   Colorectal cancer 
DISC   Death inducing signaling complex  
DCIS   Ductal carcinoma in situ 
DMEM   Dulbecco’s Modified Eagle Medium 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DTT   Dithiothreitol 
EDTA   Ethylenediamine tetraacetic acid 
EGFR   Epidermal growth factor receptor 
Et3N  Triethylamine 
EtOAc   Ethyl Acetate 
FBS   Fetal Bovine Serum 
FITC   Fluorescein Isothiocyanate 
G0/G1   phase Growth 0/ phase Growth 1 or Gap 0 phase/ Gap 1 phase 
G2/M   phase Growth 0/ Mitotic phase 
GL-261   Mouse glioma 261 cell line 
H    Hydrogen atom 
H2O   Water 
HER2+   Human epidermal growth factor receptor 2+  
HCT-116   Colorectal carcinoma cell line 
HCT-116 p53(-/-)  Human colorectal cancer cell line with null p53 
HCT-116 p53(+/+)  Human colorectal cancer cell line with wild-type p53  
Hek-293T   Human embryonic kidney cell line 
KOH  Potassium hydroxide 
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HPLC   High-performance liquid chromatography  
HR+   Hormone receptors  
Hz   Hertz  
IC50   50% of maximal inhibitory concentration 
kDa   KiloDalton 
LCIS   Lobular carcinoma in situ 
LDH   Lactate dehydrogenase 
Leu   Leucine 
MCF-7   Human breast adenocarcinoma cell line 
MDA-MB-231  Human breast adenocarcinoma cell line 
MDM2   Murine double minute-2 
MDMX   Murine double minute-X 
Me    Methyl 
mTOR   Mammalian target of rapamycin 
MTS  3-(4,5-dimetiltiazol-2-il)-5-(3-carboximetoxifenil)-2-(4-sulfofenil)-2H-
tetrazólio 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
N    Nitrogen atom 
NaCl   Sodium chloride 
NaHCO3   Sodium Bicarbonate 
NCS   N-Chlorosuccinimide 
NP-40   Nonyl phenoxypolyethoxylethanol  
NMR   Nuclear magnetic resonance 
PARP   Poly ADP ribose polymerase 
PBS   Phosphate Buffered Saline 
Ph    Phenyl 
Phe   Phenylalanine 
PI    Propidium Iodide  
PMS   Phenazine Methosulphate 
PPIs   Protein-protein interactions 
ppm   parts per million 
PS    Phospholipid phosphatidylserine 
RNase A   Ribonuclease Ribonuclease A 
ROS   Reactive oxygen species 
r.t.    Room temperature 
SAR   Structure-activity relationship 
SDS   Sodium dodecyl sulfate 
SD    Standard Deviation 
SEM   Standard Error of the Mean 
SI    Selectivity index 
S phase   Synthesis phase 
TBS   Tris-buffered saline 
TEA   Triethylamine 
temp.   Temperature 
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THF   Tetrahydrofuran 
TLC   Thin layer chromatography 
TNF   Tumour necrosis factor 
TP53    p53 protein encoding gene 
Tris-HCl   Tris-Hidroclorite 
Trp   Tryptophan 
UV   Ultraviolet 
VEGF   Vascular endothelial growth factor 
Wt    Wild-type 
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Figure 11 - Evaluation of apoptosis in human colorectal cancer cell line (HCT116 p53(+/+)) 
following 72 h incubation with 2e and 2m at equitoxic concentrations (IC50 and 2xIC50), or 
DMSO (vehicle control). **p<0.01; ***p<0.001vs DMSO. Data are mean ± S.D. of three 
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1.1. CANCER: ORIGIN, INCIDENCE AND THERAPEUTIC OPTIONS 
The maintenance of cellular homeostasis is essential for tissue integrity in multicellular 
organisms. In this regard, apoptosis, a form of regulated cell death, is an highly conserved 
mechanism that has evolved to maintain cell number and cellular positioning within tissues, 
therefore acting as a natural barrier to cancer development1,2. 
Cancer is a multifaceted and multifactorial disease comprised of complex genetic and 
epigenetic aberrations that destabilize the normal balance of cellular life and death3. The main 
causes for cancer development are the nutrition habits, specific infections such as 
Helicobacter pylori, Hepatitis B and C viruses, and Human papillomaviruses, genetic 
determinants, and others factors4–6. According to the World Health Organization, cancer is a 
leading cause of death worldwide accounting for 8.2 millions of deaths each year.  Female 
breast and colorectal cancers are among the five most  diagnosed cancers and they are also the 
main contributors for mortality and loss of healthy life4,6.  
In terms of the therapies available, they differ according to the type of cancer. Overall, 
surgery, chemotherapy, and radiation therapy are the most common treatments used against 
cancer. Chemotherapy usually refers to the use of medicines or drugs as the therapeutic agent 
and act throughout the body, meaning that it can kill cancer cells that have spread 
(metastasized) in parts of the body away from the original (primary) tumour7. Surgery and 
radiation therapy remove, kill, or damage cancer cells in a certain area. These three types of 
therapy can and are currently used in combination for better efficiency of therapy8,9. 
More recently, new forms of cancer treatment have emerged, including targeted therapy that 
uses drugs or other substances to more precisely attack cancer cells causing minor damage to 
normal cells, and immunotherapy that relies in the use of an individual’s own body immune 
system to tackle cancer. Immunotherapy may function in different ways: it can stimulate the 
immune system, or it can help the immune system to attack cancer cells. Finally, 
immunotherapy may also be used in combination with other types of treatment7. 
Cancer research has been a topic of great interest for the past decades; however, 
investment in cancer control, prevention, diagnosis and treatment is still an urgent need5. 
 
1.1.1. Colorectal Cancer 
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and presents the 
highest cause of cancer deaths10,11. CRC develops in the colon or in the rectum, also known as 
the large intestine.  
Most of the times, CRC begins as a noncancerous growth called polyp or adenoma that 
develops on the inner lining of the colon or rectum. Although all adenomas have the capacity 
to become cancerous, fewer than 10% are estimated to progress to invasive cancer. Cancer 
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that develops in glandular cells is called adenocarcinoma, which is approximately 96% of 
colorectal cancers12. 
Surgery is one of the primary options for CRC treatment, often in combination with 
radiation therapy and chemotherapy. The most often used drugs for colorectal cancer include: 
5-Fluorouracil (5-FU); Capecitabine, which is in pill form and once in the body is converted 
to 5-FU; Irinotecan; Oxaliplatin; and Trifluridine and tipiracil (Lonsurf), a combination drug 
in pill form. Sometimes, two or more of these drugs are combined to achieve more efficacy. 
Targeted therapy drugs work differently from standard chemotherapy drugs. Sometimes 
they are effective when standard chemotherapeutics drugs are not, and they often have 
different and less severe side effects. Currently, the most commonly used target cells with 
EGFR changes and the blood vessel formation (VEGF) where the Cetuximab (Erbitux) and 
the Bevacizumab (Avastin) are used. These drugs can be used in combination with 
chemotherapeutic drugs or alone if chemotherapeutic drugs are no longer effective13. 
 
1.1.2. Breast Cancer 
Breast cancer is a heterogeneous disease with a wide spectrum of clinical, pathologic, and 
molecular features. Although it is much more frequent in women, men can also develop the 
disease14. The majority of breast cancers begin in the lobules and ducts where the mammary 
glands are located15,16. Breast cancer can be defined as in situ or invasive depending on its 
extension.  
 
In situ breast cancer 
Ductal carcinoma in situ (DCIS) is when abnormal cells replace the normal epithelial 
cells of the breast ducts. It is considered a non-invasive form of breast cancer and is the most 
common type of in situ breast cancer, representing about 83% of diagnosed cases. DCIS may 
or may not progress to invasive cancer and, in fact, some of these tumours grow so slowly 
that they may not affect the woman’s health even without treatment. 
Lobular carcinoma in situ (LCIS), also known as lobular neoplasia, generally is not 
considered a precursor of invasive cancer. Instead, it represents an indicator for increased risk 
for developing invasive cancer. LCIS accounts for about 13% of all female in situ breast 
cancers diagnosed. 
 
Invasive breast cancer 
The majority of breast cancer cases are invasive, or infiltrating, meaning that they have 
broken through the walls of the glands or ducts where they were originated, and have grown 
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into the surrounding breast tissue. Based on comprehensive gene expression profiling, breast 
tumours are classified into several subtypes: luminal and human epidermal growth factor 
receptor 2+ (HER2+), depending on if they express hormone receptors (HR+) and HER2, 
respectively15,16. Approximately 74% of all breast cancers are Luminal A (HR+/HER2-). 
These tumours tend to grow slowly and are less aggressive than other subtypes, probably 
because they are responsive to hormonal therapy16,17. Conversely, the triple negative tumours 
(HR-/HER2-) are the most aggressive, in part due to lack of specific therapies16,17. 
The majority of breast cancers are treated surgically, which can be often combined with 
radiation therapy, chemotherapy, hormonal (endocrine) therapy, and/or targeted therapy16,18. 
The benefit of different types of therapies depend on multiple factors, such as the size of the 
tumour, the number of lymph nodes involved, the presence of estrogen or progesterone 
receptors, and the amount of HER2 protein produced by cancer cells. For example, the triple 
negative and HER2+ breast cancers tend to be more sensitive to chemotherapy. Some 
examples of chemotherapeutics used are Paclitaxel, Carboplatin, 5-fluorouracil, Docetaxel 
among others16,18. 
There is yet, targeted therapy which is divided in two principal targets: targeted therapy 
aimed at HER2-positive where Trastuzumab, Pertuzumabre are used and targeted therapy for 
hormone receptor-positive using Everolimus and Palbociclib16,18. 
 
1.1.3. Glioblastoma 
The brain is the most complex organ in vertebrates. It is composed primarily of two broad 
classes of cells, neurons and glial cells, which can develop into different types of tumours. 
The majority of brain tumours develop from glial cells that include astrocytes, 
oligodendrocytes, microglia and ependymal cells. Therefore, glioma is a generic term used to 
describe the different types of glial tumours: astrocytoma, oligodendroglioma, and 
glioblastoma. The most frequent and malignant of all is glioblastoma19. 
All the types of treatment referred before can be used in brain and spinal cord tumours. 
Each treatment is based on the type of tumour and other factors, and often, more than one 
type of treatment is used.  Some of the chemotherapeutic drugs used to treat brain tumours 
include cisplatin, irinotecan and others, such as temozolomide. For example, temozolomide 
acts by inducing cytotoxicity through pro-autophagic processes and also through the induction 
of apoptosis. Of note, autophagy is a type II programmed cell death that represents an 
alternative mechanism to overcome, at least in part, the resistance of many cancers to 
apoptosis-related therapies. On the other hand, targeted therapy targets vascular endothelial 
growth factor (VEGF) and (mammalian target of rapamycin) mTOR18,20,21. 
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1.2. CANCER BIOLOGY: PATHWAYS AND MECHANISMS 
Tumourigenesis is a multistep process of acquiring successive genetic mutations that 
transform a normal cell into a cancer cell. These mutations give rise to hyperproliferative 
signals that sustain and enable the immortality of cells through an unlimited replicative 
potential, the invasion and metastization ability, the insensitivity to growth suppression 
signals, the resistance to cell death and the induction of tumour angiogenesis2,22. Deregulated 
expression of transcription factors during tumourigenesis is essential for the promotion of 
proliferation and differentiation of a neoplastic population22. 
 
1.2.1. Apoptosis 
Cell death by apoptosis, is the principal strategy to control tumour development, in which 
cells receive specific stimuli to die. These stimuli are part of an important program of cell 
growth control, characterized by morphologic as well as biochemical changes. Apoptosis can 
occur by two major signalling pathways, the death receptors or extrinsic pathway, and the 
mitochondrial or intrinsic pathway. Overall, these two pathways are distinct, but ultimately 
converge to the same mechanism. The apoptotic process culminates in activation of a series of 
cysteine aspartyl-specific proteases, or caspases, that cleave key cellular proteins like 
polyADP-ribose polymerase (PARP) (Figure 1). Activation of caspases is considered the 
point of no-return, in which cell death becomes an irreversible process23,24. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Illustration of the two major apoptotic signalling pathways. Apoptosis can be initiated by two 
alternative pathways: via death receptors on the cell surface (extrinsic pathway) or by mitochondria (intrinsic 
pathway). In both pathways, induction of apoptosis leads to the activation of an initiator caspase. The two 
pathways are correlated since caspase-8 (extrinsic pathway) activates the intrinsic pathway for cleavage of Bid, 
Bcl2 family member. Adapted from 116. 
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Extrinsic or Cell Death Receptor Pathway 
The extrinsic or cell death receptor pathway is initiated by extracellular signals, resulting in 
binding of ligands to specific transmembrane receptors, collectively known as death 
receptors, belonging to the tumour necrosis factor (TNF) family. The death receptors are cell 
surface receptors that transmit apoptotic signals from the cell surface to activate intracellular 
signalling pathways25. 
All death receptors work in a similar manner, via conformational changes that allow the 
assembly of a large multiprotein complex known as DISC (Death-Inducing Signalling 
Complex), ultimately leading to the activation of the caspase cascade. Pro-caspases are 
recruited to the DISC and subsequently are cleaved to result in active initiator caspases, 
including caspase-8 and -10, this initiator caspases have the ability to cleave and activate 
effectors caspases, such as caspase-3 and -7. Importantly, the extrinsic pathway is able to 
crosstalk with the intrinsic or mitochondrial pathway, thus amplifying the death signal25–27. 
 
Intrinsic or Mitochondrial Pathway 
The intrinsic apoptotic pathway is initiated by a non-receptor mediated stimuli that triggers 
intracellular signalling. Mitochondria activation in the intrinsic pathway is mediated by the 
Bid protein, a pro-apoptotic member of the Bcl-2 family. Bid is cleaved indirectly by p53 and 
directly by active caspase-8, and subsequently translocated to the mitochondria. The presence 
of cleaved Bid in the mitochondrial membrane regulates mitochondria permeabilization. 
When an apoptotic stimuli reach the mitochondria, a variation of the inner mitochondrial 
membrane potential occurs, as well as changes in the membrane permeability, leading to the 
passage of water and consequently organelle’s rupture. Consequently, mitochondria release 
pro-apoptotic factors into the cytoplasm, including cytochrome c, which together with the 
destabilization of the membrane potential leads to loss of cellular homeostasis, disruption of 
ATP synthesis and increased reactive oxygen species (ROS) production. The increase of ROS 
levels then leads to lipid, protein and nucleic acid oxidation by increasing the collapse of the 
inner mitochondrial membrane potential. Cytosolic cytochrome c also interacts with apoptotic 
protease activating factor 1 (Apaf-1) and pro-caspase 9, in the presence of ATP, to form a 
complex known as apoptosome. After that, caspase-9 is activated and subsequently activates 
effector caspases for the execution of apoptosis25–28. 
 
1.3. p53 – THE TUMOUR SUPPRESSOR PROTEIN AND TUMOURIGENESIS  
p53 tumour suppressor protein is regarded as a key player in tumour suppression, as it 
promotes growth arrest, apoptosis and cellular senescence, while also blocking 
angiogenesis29,30. Strikingly, half of all human tumours carry p53 inactivated by mutation 30–
32
, while the other half refers to tumours in which the p53 pathway is partially abrogated by 
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inactivation of other signaling components, such as p53 endogenous negative regulators 
murine double minute 2 (MDM2) and/or MDMX 29,32,33.  
In some cases, frameshift or nonsense mutations result in the loss of p53 protein 
expression. However, missense mutations that lead to the substitution of a single amino acid 
in the p53 protein, can be stably expressed in tumours cells resulting in novel functions for 
p5334,35. These substitutions may occur throughout all the structural domains of p53 protein, 
but they are more frequently clustered within the DNA binding region of p53. These 
mutations generally lead to a loss or diminution of the wild-type activity of p5334. Although 
mutations have been detected in almost all of the p53 amino acids, a number of hotspot sites 
have been identified, especially at residues R175, G245, R248, R249 and R27333,36. 
p53 has been called "guardian of the genome", due to its  central role in coordinating 
the cellular response to a wide range of cellular stress37. One of the main functions of p53 is 
as transcription factor that both activates and represses an ample range of target genes37.  The 
regulation of p53 function has been described at multiple levels and consists in an array of 
post-translational modifications, that lead to protein accumulation and increase of its 
transcriptional activity, both during normal homeostasis as in stress-induced responses31,37 
(see Figure 2). Even though, the key mechanism by which p53 is regulated is through control 
of its protein stability, mediated primarily by MDM2. 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Action of p53. A wide range of cellular stress stimuli induce p53, leading to co-ordinated changes 
in gene expression and various biological outcomes, depending on the cell type and the type, intensity and 
duration of the activating stress. Those events that induce p53 through the DNA-damage-response pathways 
are highlighted on the left-hand side in lilac. Regulation of some biological events may occur in a homoeostatic 
manner mediated by basal or low levels of p53. Adapted from117. 
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As the p53 is frequently mutated or inactivated in cancer, this tumour suppressor has 
turned into a highly attractive therapeutic target for the treatment of the disease. Several 
studies have shown that p53 interaction with MDM2 and MDMX involves three main 
hydrophobic amino acids (Phe19, Trp23 and Leu26) in the p53 protein38–40. In case of cellular 
stress, these interactions should be inhibited to activate the p53 response31. For that purpose, 
small molecules that mimic the three amino acid residues of p53-MDMs binding pocket have 
been widely developed and tested as potential antitumour agents38. 
Further, as mutant p53 has been reported to confer drug resistance in different cancer 
therapies, its reactivation or neutralization can be beneficial in this context33. 
 
1.4. NEGATIVE REGULATORS OF p53 
Protein-protein interactions (PPIs) have an important role in cancer because they regulate 
various cellular processes, particularly in cell cycle or cell signalling pathaways41. 
The small molecule inhibitors of protein-protein interactions have received considerable 
interest in the last years. In particular, the inhibitory interaction of p53 with regulatory 
proteins, MDM2 and MDMX, provided a focus of effort due to its importance in various 
types of cancer, and the prospect that inhibition of these interactions may provide new 
therapies42. 
The MDM´s proteins are present at high levels and inhibit activity p53 in many human 
cancers. Thus, interrupting the p53-MDM interaction to reactivate p53 is a valuable 
therapeutic strategy for the treatment of tumours43. 
Several studies currently focus on the design of small inhibitory molecules of both MDM´s 
(MDM2 and MDMX). Despite the efforts, there are no compounds in clinical stages for this 
purpose, since existing compounds for inhibiting MDM2 are inefficient in the inhibition of 
MDMX44. This problem derives, at least in part, from the "sub-pocket" Leu26 that represents 
the greatest challenge to design a dual inhibitor of MDM2/MDMX. The two proteins 
significantly differ in shape and in the properties of the residues surrounding the cavity39,44–46. 
Therefore, the development of specific inhibitors for MDMX must take into account their 
unique structural properties that go beyond this "simple" difference. The well-defined binding 
furrows in MDM´s suggest the feasibility of designing small-molecule inhibitors to block 
their interaction with p5339. 
 
1.5. p53-MDM2/MDMX PROTEIN-PROTEIN INTERACTION 
The information of diverse proteins correlating their function in the tumour environment is 
emerging as an important aspect of studying protein function in cancer. The structural 
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changes of protein in the course of mutation with its altered cellular localization is a important 
point to understand better the progression of the disease22.  
MDM2 belongs to the family of E3 ubiquitin ligase that contains a  RING 
(really interesting new gene) domain and serves as the major ubiquitin ligase for p53 
degradation32,39,47.  
The MDM2 protein binds directly to the N-terminal domain of p53, thus inhibiting its 
transcriptional activity through multiple mechanisms including, direct occlusion of p53 
transactivation domain, induction of p53 nuclear export and target of p53 for proteasomal 
degradation32,39. However, recent research has demonstrated that MDM2 alone is 
insufficient to suppress p53 activity32. 
Under normal conditions, MDM2, which is itself a product of a p53 target gene, inhibits 
the activity of p53 by physical interaction48. This inhibition is accomplished through a 
negative autoregulatory feedback loop in which p53 activates the transcription of its own 
inhibitor, as mentioned above. Therefore, in non-stressed cells, the low level of MDM2 
mediate multiple mono-ubiquitination of p53, promoting its nuclear export29,37,49 (Figure 3).  
When cells are challenged by a stress insult, p53 levels are rapidly up-regulated to enable 
repair. Meanwhile, the expression levels of MDM2 in cells under stress are also higher 
promoting the poly-ubiquitination and degradation of p53 after the repair has occurred. In the 
cytosol, mono-ubiquitinated p53 induces Bax oligomerization followed by mitochondrial 
translocation, eventually leading to the release of cytochrome c and other pro-apoptotic 
molecules into the cytosol. These mechanisms show that p53 ubiquitination by MDM2 is 
another layer of p53 activity regulation31,37,49, further demonstrating the importance of p53-
MDM2 binding as a therapeutic target in cancer. 
MDM2 also interacts with its equivalent MDMX through the RING domain31. 
In the same way that MDM2, MDMX is an important negative regulator of p53. MDMX is 
a homologue of MDM2, in particular in the domain that binds to p53. Nevertheless, both 
proteins present enough differences to turn p53-Mdm2 inhibitors ineffective in inhibiting p53-
MDMX interaction.  It has been demonstrated that MDM2 regulates p53 mainly by protein 
degradation, whereas MDMX is a potent inhibitor of its transcriptional activity50. In fact, 
unlike MDM2, MDMX does not have appreciable ubiquitin ligase activity44. Another key 
difference between Mdm2 and MDMX is that MDMX is primarily located in the cytoplasm, 
while MDM2 is located in the nucleus. MDMX nuclear translocation may occur to form the 
complex MDM2/MDMX and inhibit p5331. The formation of MDM2/MDMX heterodimers 
through the RING domains participate in p53 poly-ubiquitination and proteasomal 
degradation. In response to DNA damage signals, MDM2/MDMX heterodimers are poly-
ubiquitinated, resulting in degradation of the complex and consequent p53 stabilization and 
activation45,49 (Figure 3). 
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In addition to having its own effects on p53, MDMX also plays an important role in 
stabilizing the MDM2 protein. Taking into account the role of MDMX in inhibiting p53, 
several molecules are being developed for MDMX inhibition. 
In Table 1, are presented the main inhibitors developed for inhibition of the interactions 
between p53 and MDM´s proteins (Table 1). 
 
 
 
 
 
Figure 3 - Schematic diagram of p53 degradation regulated by MDM2 and MDMX. In unstressed conditions, 
p53 fails to accumulate due to constitutive degradation. Under genotoxic stress, cells activate an evolved 
response for MDMX degradation that stabilizes p53 and activity. U - ubiquitination. 
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Table 1 – Main MDM´s antagonists51. 
 
 
1.6. INHIBITORS OF p53-MDM2 INTERACTION 
To date, there are over 20 different chemotypes that have been shown to antagonise the 
p53-MDM2 interaction, such as cis-imidazolines52 (eg, RG-7112), benzodiazepinediones53 
(eg, TDP665759), spiropyrrolidine oxindoles54 (eg, MI-77301), and piperidinones55 (eg, 
AMG-232) (see Figure 4.2). Although these compounds share different scaffold structures, 
they all inhibit the p53-MDM2 interaction by mimicking the three hot spots residues of p5339 
(figure 4.1). 
 
 
 
 
1.6.1. Cis-Imidazolines (Nutlins) 
The nutlins (cis-imidazolines) were identified as the first class of potent, non-peptide and 
specific small molecule MDM2 inhibitors, from a large chemical screen and chosen for their 
potency and selectivity for inhibition of the p53-MDM2 interaction35,39. Nutlin-3a, arrests 
proliferating cancer cells in the G1 and G2 cell cycle phases as well as induces apoptosis in 
Strategy Compound 
Interruption of p53 interaction with 
MDM2 
Small molecules that bind the MDM2 N_ pocket: 
Nutlin-3a/RG7112, MI-219, MI-63, MI-319, MI-773, 
AM-8553, AMG-232, benzodiazepinediones, MK-
8242 Small molecules that bind the p53 N-terminal 
domain: RITA 
Interruption of p53 interaction with 
MDMX Small molecules: WK 298, SJ-172550 
Interruption of p53 interaction with 
both MDM2 and MDMX 
Peptidic compounds: SAH-p53s, PMI peptide, pDI 
peptide 
Small molecules: RO-5963, CGM097 
Figure 4 - 4.1) p53 structure (pink) with three hydrophobic residues Phe19 (Green), Trp23 (Yellow) and Leu26
(Orange). Image obtained using the UCSF Chimera software. 4.2) Chemical structures of: A) MI-77301, B) 
RG-7112, C) TDP665759, D) AMG-232 mimic the three hydrophobic residues Phe19 (Green), Trp23 (Red) and 
Leu26 (Blue). Image obtained using the ChemDraw software. 
4.1) 4.2) 
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wild-type p53 dependent manner, in a number of different cancer cell lines expressing wt-p53 
including colorectal, lung, breast, prostate, melanoma, osteosarcoma and renal cancer35,56. 
Further structure-based optimization of nutlin-3a led to compound RG-7112, the first 
MDM2 inhibitor advancing into clinical trials. In fact, RG-7112 presented  enhanced binding 
affinity to MDM2 and more potency to inhibit wild-type p53 tumour growth35,39,57. 
 
1.6.2. Benzodiazepinediones  
The Benzodiazepinediones disrupt the p53-MDM2 interaction in a similar manner to the 
nutlins, by mimicking the action of the key amino acids involved in the binding of the p53 
peptide to MDM235. One of these compounds is TDP66575953, which binds to the binding 
cleft of MDM2, predominantly hydrophobic, and occupies the same pockets as the peptide 
side chains Phe19, Trp23, and Leu26 of p53. MDM2 interacts with the inhibitor through 
nonspecific Van Der Waals contacts58. 
 
1.6.3. Piperidinones 
Compound AMG-232, was obtained by a structure-based design and wide optimization of 
a new class of MDM2 inhibitors containing a piperidinone scaffold. AMG-232 has entered in 
phase I clinical trials for human cancer treatment in 2012. In this compound the 3-
chlorophenyl and 4-chlorophenyl groups are project into the Leu26 and Trp23 pockets, 
respectively. The Phe19 pocket is occupied by the ethyl group. The sulfonyl tert-butyl group 
resides in the small pocket around G58, and the carboxylic acid forms a salt bridge with the 
His96 residue of MDM2, increasing the inhibitory effect of the compound on MDM2. Thus, 
AMG-232 not only mimics the three key p53 residues but captures additional interactions to 
achieve a very high binding affinity with MDM257,59. 
 
1.6.4. Spiropyrrolidine oxindoles 
In the past years, several classes of small molecule inhibitors that disrupt p53-MDM2 
binding, such as MI-219, have been revealed. Extensive optimization of spiropyrrolidine 
oxindoles family has yielded SAR405838 (MI-77301). This compound is in phase I of clinical 
trials for neoplasm malignant60.  Before going to clinical trials, its ability to inhibit cancer cell 
proliferation and to inhibit tumour growth in xenograft models was reported. A good tissue 
bioavailability in mice, a desirable pharmacokinetic profile and an orally activity, were also 
reported for MI-7731054. 
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1.6.5. Dual Inhibitors 
The need for a compound with a double ability for MDM2 and MDMX, led to the 
discovery of compound, RO-2443 that showed potent MDM2/MDMX inhibitory activity in 
vitro, but poor water solubility. Optimization of RO-2443 yielded RO-5963, a close analogue 
with slightly increased potency but substantially improved solubility. RO-5963 (figure 6) also 
showed p53-MDM2 inhibitory activity similar to that of nutlin-3a and p53-MDMX inhibitory 
activity was nearly equivalent to MDM2 activity but approximately 400-fold better than the 
MDMX potency of nutlin-3a39,44. 
Studies have shown that RO-5963, inhibits cell growth, stabilizes p53 in a dose-dependent 
manner, and elevates protein levels of its transcription targets (p21 and MDM2). 
The RO compounds binding method is really interesting because, sub-pocket Leu26 is not 
occupied by these compounds. They have a very high affinity to both MDM2 and MDMX 
proteins, through their chloro-indole and di-fluoro-phenyl moieties, which fill Phe and Trp 
sub-pockets, respectively. These compounds also show, a high activity in cellular line cancer 
cells lines with wt-p5344. 
A new class of molecules that mimic p53 α-helix, the pyrrolopyrimidines (Figure 5), and 
show effect on both MDM2 and MDMX proteins. These new molecules mimic α-helixes, 
secondary structures of most common proteins, which are involved in several protein-protein 
interactions (PPI).  Pyrrolopyrimidines have several advantages over the majority of 
structures known as PPI inhibitors, such as improved aqueous solubility, excellent cell 
permeability and synergistic effect over MDM2 and MDMX61. 
 
 
 
 
 
 
 
 
Figure 5 - Chemical struture of: A) and B) pyrrolopyrimidines; C) RO-5963 mimic the three hydrophobic 
residues Phe19 (Green), Trp23 (Red) and Leu26 (Blue).  Image obtained using the ChemDraw software. 
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The main objective of the studies presented in this thesis was the development and 
optimization of new anticancer agents that potentially target the molecular interaction 
between p53 tumour suppressor and its main negative regulators, MDM´s. Our strategy 
involved not only the chemical synthesis, but also the biological activity evaluation of the 
newly synthesized compounds, using several cellular models. 
Primarily, we aimed at developing a novel spirooxindole scaffold containing a pyrazoline 
ring that functions as the rigid heterocyclic scaffold, from which the three lipophilic groups 
can be projected to mimic the p53 amino acids.  
Secondly, we decided to study the biological effect of changing the CH-4´ (pyrazoline) by 
a N-4´ (tryazoline) on the five-member ring of the spirooxindole skeleton. 
In parallel, we performed a broad range of molecular and biochemical studies to dissect the 
cellular mechanisms triggered by the most potent compounds. More specifically, our goals 
were to: 
- Evaluate the antiproliferative capacity of the compounds in several cancer cell lines as 
well as in normal cells; 
- Evaluate their ability to induce cell death, in particular apoptosis, and/or cell cycle 
arrest; 
- Determine whether the compounds inhibit p53-MDM2 interaction; 
- Evaluate the potential synergistic effect between the most potent molecule and a 
chemotherapeutic drug already in use; 
- Assess compound stability in saline solution. 
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SPIROPYRAZOLINE OXINDOLES: 
DESIGN AND EVALUATION 
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Spirooxindoles are reported as the core structure of a variety of medicinal agents with 
several applications, such as anticancer agents62. These molecules have a big potential 
because the oxindoles moiety can mimic the p53 Trp23 sub-pocket. Another advantage of 
spirooxindoles, is that some derivatives were described to have specificity against cancer cell 
lines and not against normal epithelial cells35,57,63–66. This chemical structure is considered an 
important heterocyclic molecule, which belongs to a large family of bioactive compounds, 
such as compounds MI-77301 and RO-535365,67. 
Pyrazoline is also a privileged unit in medicinal chemistry, and is described to have anti-
viral, anti-tumour, antibacterial, anti-inflammatory, and anti-fungal activities68. 
These two units are structural parts of our compounds, the spiropyrazoline oxindoles 
(Figure 6). 
 
 
 
Figure 6 – a) Spirooxindole stucture; b) Pyrazoline structure. 
  
In the last years, Santos’s group (iMed.ULisboa) has been investigating the potential of 
several families of spirooxindoles with 5-membered rings as potential anti-cancer agents. 
Previous work from the research group shown that spiroisoxazoline oxindoles 169 and 
spiropyrazoline oxindoles 270 have in vitro anticancer properties.  
 
 
 
 
 
Spiroisoxazoline oxindoles 1 presented ability to disrupt the p53-MDM2 interaction, as 
determined by a Venus-based bimolecular fluorescence complementation assay (BiFC).  
However, the IC50 values were very high compared with other spirooxindoles described in the 
literature (around 40µM for the colorectal cancer cell line HCT-116). Computational studies 
showed that the optimal Trp23 mimicry by the oxindole was lost due to the spatial orientation 
of the groups: oxindole R2 and R3. Instead, these molecules, the oxindole is projected into 
Phe19(p53) pocket, while aromatic substituent’s R2 and R3 are projected into Trp23(p53) and 
Leu26(p53) pockets, respectively71. However, the inclusion of a fourth substituent to the main 
Scheme 1 - Optimization strategy: from spiroisoxazoline 1 to spiropyrazoline 2 oxindoles.  
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scaffold and the substitution of the isoxazoline oxygen atom for a N-Ar group could allow a 
potential reorientation of the ligands in the MDM2 pocket (Scheme 1).  
In this thesis, a family of spirooxindoles containing a five ring (pyrazoline) was 
synthesized and the antiproliferative activity evaluated. Previously, some spiropyrazoline 
oxindoles 2 were tested against the MCF7 and MDA-MB-231 breast cancer cell lines, and the 
most active compounds showed an IC50 value around 7µM, and were selective over MDA-
MB-231 tumour cells and non-cytotoxic against Hek-293T non-tumour cells. Therefore, in 
this work, we developed and optimized the previously developed spiropyrazoline oxindoles 
and assessed their biological effects. 
 
0.1. SYNTHESIS OF THE TARGET COMPOUNDS 
p53 interacts with MDM2 through the residues Phe19, Trp23 and Leu26 that occupy the 
hydrophobic cleft of the MDM2 protein. These three residues represent the critical ones for 
binding between these two proteins. Having this into account 2-indolinones 3a-h and 
hydrazonyl chlorides 4a-e, containing substituent’s to mimic these important aminoacids, 
were synthesized (Tables 2 and 3). The R1 in indole part of the compounds mostly presents 
halogens as the main choice. This choice was based on previous reports of potent MDM2 
inhibitors (example MI-77301, SM13) that contain halogens in the indole moiety. The R2, R3 
and R4 were synthesized taking into account the ability of an halogenated 5-membered 
aromatic ring to insert into Phe19 pocket, and an often branched aliphatic moiety or an often 
halogenated 5-membered aromatic ring to occupy the Leu26 pocket65,72. 
 
Spiropyrazolines´ 2 have a basic molecular structure derived from the corresponding 
pyrazoline and are exemplified by a unique spiro junction at the C-5 position of a pyrazoline 
ring. The 1,3-dipolar cycloaddition is a very useful reaction for the synthesis of spirooxindole 
ring systems62,66,73–75. 
The synthetic strategy employed to synthesize spiropyrazolines oxindoles 2a-x is depicted 
in scheme 2. The final spiropyrazoline oxindoles 2 were obtained by 1,3-dipolar cycloaddition 
between 2-indolinones 3a-h and nitrile imines 5 (generated in situ by dehydrohalogenation of 
hydrazonyl chlorides 4a-e) (Scheme 2). 
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Scheme 2 - Synthesis of spiropyrazoline oxindoles 2a-x. (a) aromatic aldehydes, piperidine, EtOH in reflux; (b) 
Et3N/DIPEA, CH2Cl2, r.t. 
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The 2-indolinones 3a-h containing R2 aromatic groups, were synthesized by aldolic 
condensation reaction of substituted indolin-2-ones 6 with different aromatic aldehydes in the 
presence of piperidine70,76–79 with yields between 30 – 93% (Table 2). Additionally, indolin-2-
one 3e was generated using 5-bromo isatin in the presence of hydrazine monohydrate and 
ethylene glycerol, under reflux80. 
 
Table 2 - Synthesis of 2-indolinones 3a-3h. 
 
 
 
 
 
The dipole required for the synthesis of the final compounds, through a 1,3-dipolar 
cycloaddition, was obtained in situ from hydrazonyl chlorides 4b, 4d and 4e75. These 
molecules were synthesized by Appel reaction, where hydrazone reacts with 
triphenylphosphine and carbon tetrachloride (Scheme 3.b). Hydrazonoyl 7 was obtained by 
reaction of phenylhydrazine with trimethylacetyl chloride (Scheme 3.a)75,81.  
 
 
 
 
 
 
 
 
 
 
 
 
Compound R1 R2 Yield (%) 
3a H  Ph  80 
3b 5-Cl  Ph  72 
3c 6-Cl  Ph  92 
3d 7-Cl  Ph  74 
3e 5-Br  Ph  46 
3f 6-Br  Ph  82 
3g 6-Cl, 5-F  Ph  30 
3h 6-Cl  Ph-m-Cl  93 
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Scheme 3 - Synthesis of hydrazonoyl 7 and hydrazonyl chlorides 4. (a) aqueous ethanol 20%, r.t., 2-3h, 81-
99%; (b) NCS, S(CH3)2, 0ºC, 15 min; -78ºC, 1h, then allowed to warm up to r.t., 62-88%. 
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They can be, also, synthesized by reacting N-chlorosuccinimidedimethyl sulphide complex 
8, prepared in situ from the appropriate hydrazones 9 at -78 ºC82, resulting in hydrazonyl 
chlorides 4a and 4c with yields between 33 - 96% (Table 3). 
 
Table 3 - Synthesis of hydrazonyl chlorides 4. 
 
 
 
 
Finally, spiropyrazoline oxindoles 2 were obtained with yields between (27.5 – 97.8 %) 
(Table 4). 
 
Table 4 - Yields obtained in the synthesis of spiropyrazoline oxindoles 2a-2x. 
 
 
 
 
 
 
 
 
 
 
 
 
The spiropyrazoline oxindoles 2a-x were characterized by NMR. In general, in the 13C-
NMR, the spiro carbon appeared between 75.66 – 78.98 ppm and the C-4’ between 61.02 - 
63.22 ppm. Additionally, the pyrazoline C=N appeared between 148.13 – 164.32 ppm and the 
carbonyl C=O between 176.36 - 178.62 ppm. 
Compound R3 R4 Yield (%) 
4a Ph  Ph  86 
4b Ph  Ph-o-Cl  80 
4c Ph-p-O-CH3 Ph  33 
4d t-Bu  Ph  44 
4e t-Bu  Ph-o-Cl  52 
Compound R1 R2 R3 R4 Yield (%) 
2a H Ph Ph Ph 78 
2b 5-Cl Ph Ph Ph 82 
2c 6-Cl Ph Ph Ph 83 
2d 7-Cl Ph Ph Ph 92 
2e 5-Br Ph Ph Ph 82 
2f 6-Br Ph Ph Ph 84 
2g 6-Cl, 5-F Ph Ph Ph 40 
2h 7-Cl Ph Ph Ph-o-Cl 94 
2i H Ph Ph-p-O-CH3 Ph 74 
2j 5-Cl Ph Ph-p-O-CH3 Ph 33 
2k 7-Cl Ph Ph-p-O-CH3 Ph 71 
2l 6-Br Ph Ph-p-O-CH3 Ph 92 
2m 6-Cl Ph-m-Cl Ph-p-O-CH3 Ph 98 
2n H Ph t-Bu Ph 73 
2o 5-Cl Ph t-Bu Ph 80 
2p 6-Cl Ph t-Bu Ph 79 
2q 7-Cl Ph t-Bu Ph 87 
2r 5-Br Ph t-Bu Ph 42 
2s 6-Br Ph t-Bu Ph 92 
2t 6-Cl Ph-m-Cl t-Bu Ph 83 
2u H Ph t-Bu Ph-o-Cl 62 
2v 5-Cl Ph t-Bu Ph-o-Cl 28 
2x 7-Cl Ph t-Bu Ph-o-Cl 71 
39 
13C NMR spectra obtained for spiropyrazoline oxindole 2g, shown the spiro carbon at 
77.01 ppm, the signal of C-4’ at 5.08 ppm, the signal of the pyrazoline C=N at 149.23 ppm 
and the signal of the carbonyl at 178.47 ppm (Figure 7). 
 
In the 1H-NMR, the most characteristic signal was the one of H-4’ , which appeared 
between 4.39 – 6.82 ppm70,83. Below it is presented the 1H NMR spectra obtained for 
spiropyrazoline oxindole 2g. The most characteristic proton is H-4’ at 5.08 ppm (Figure 8).  
 
4  ´
Figure 8 - 1H NMR spectra of compound 2g. 
Figure 7 - 13C NMR spectra of compound 2g. 
4´ 
40 
 
3.2. BIOLOGICAL EVALUATION - COLORECTAL AND BREAST CANCER 
CELL LINES 
0.2.1. Antiproliferative Assays and SAR Studies 
p53 mutations remain the most common genetic change identified in human neoplasia. The 
status of p53 mutation is closely related to the progression and outcome of colorectal cancer, 
and approximately half of all colorectal cancers have p53 gene mutations (TP53). In breast 
cancer, both the overall survival rate and the aggression level of the disease are closely related 
with mutations in p53 and nearly 30% of the patients have TP53 mutated. 
In order to evaluate the antiproliferative potential of spiropyrazoline oxindoles derivatives, 
we used different cancer cell lines with different TP53 status. Taking into account the 
previous information about the importance of p53 in both colorectal and breast tumours, the 
cell lines selected for the antiproliferative assays were the HCT-116 human colorectal cell line 
harbouring wild-type p53 (HCT-116 p53(+/+)) or lacking p53 (HCT-116 p53(-/-)),  and the 
MCF-7 and MDA-MB-23 human breast cancer cell lines expressing wild-type p53 or a 
mutated form, respectively. 
The antiproliferative potential of compounds 2a-2x was first evaluated in HCT-116 
colorectal cancer cells, using the MTS metabolism assay. Taking into account that some 
compounds (2a-2f, 2j-2l, 2p, 2q and 2s) of this family had been previously tested in human 
breast cancer cell lines (MCF-7 and MDA-MB-231)70, compounds 2g-i, 2m-o, 2r and 2t-x 
were also tested in these same cell lines. From the results obtained, we determined the relative 
IC50 values (Table 5), which prove themselves fundamental for the validation and 
characterization of the compounds. 
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Table 5 - In vitro antiproliferative activities of spiropyrazoline oxindoles 2a-x. 
[a] IC50 determined by the MTT method after 48h compound incubation. Each value is the mean (IC50 ± SD) of three independent 
experiments; [b] IC50 determined by the MTS method after 72h compound incubation. Each value is the mean (IC50 ± SD) of three 
independent experiments performed in duplicate. N.D - not determined. SI - Selectivity index towards MDA-MB-231 between cancer cell 
lines, expressed by the ratio MDA-MB-231 IC50/MCF-7 IC50. 
 
 
 
 
 
 
 
 
 
 
Breast cancer cell lines Colorectal cancer cell 
lines 
“Normal” 
cell line  
Compound R1 R2 R3 R4 
MCF-7 
IC50, µM[a] 
MDA-MB-231 
IC50, µM[a] 
HCT 116 
p53(+/+) 
IC50, µM[b] 
HCT 116 
p53(-/-) 
IC50, µM[b] 
Hek-293T 
IC50, µM[a] 
SI 
2a H Ph Ph Ph ˃100 N.D. ˃20 N.D. N.D. N.D. 
2b 5-Cl Ph Ph Ph 37.7±14.1 N.D. 11.0±0.3 14.3±3.1 N.D. N.D. 
2c 6-Cl Ph Ph Ph 27.1±8.2 ˃50 16.7±0.9  17.0±0.9  ˃50 1.8 
2d 7-Cl Ph Ph Ph 22.4±3.5 16.9±1.2 16.6±1.5 17.1±1.4 ˃100 < 1.0 
2e 5-Br Ph Ph Ph 7.3±1.4 ˃100 13.1±1.0 14.2±0.8 ˃100 13.7 
2f 6-Br Ph Ph Ph 9.6±1.0 8.3±1.2 15.9±0.6  16.4±0.6  28.9±1.2 < 1.0 
2g 6-Cl, 5-F Ph Ph Ph N.D. N.D. 12.4±0.7 15.2±1.6 N.D. N.D. 
2h 7-Cl Ph Ph Ph-o-Cl N.D. N.D. ˃20 N.D. N.D. N.D. 
2i H Ph Ph-p-O-CH3 Ph ˃50 N.D. 11.7±0.3 14.7±0.3 N.D. N.D. 
2j 5-Cl Ph Ph-p-O-CH3 Ph 33.9±15.4 N.D. 10.6±1.5 13.9±2.0 N.D. N.D. 
2k 7-Cl Ph Ph-p-O-CH3 Ph 11.5±1.6 ˃100 15.6±0.9 16.4±0.8 ˃100 8.7 
2l 6-Br Ph Ph-p-O-CH3 Ph 7.0±1.1 28.7±1.1 12.8±0.7 10.0±0.6 ˃100 4.1 
2m 6-Cl Ph-m-Cl Ph-p-O-CH3 Ph ˃50 N.D. 10.9±0.8 11.6±0.8 N.D. N.D. 
2n H Ph t-Bu Ph 16.9±3.7 13.9±2.9 ˃20 N.D. 10.9±1.7 < 1.0 
2o 5-Cl Ph t-Bu Ph 12.0±3.7 14.4±2.6 17.±1.3 16.6±1.5 16.4±1.9 1.2 
2p 6-Cl Ph t-Bu Ph 25.8±4.0 ˃50 ˃20 N.D. ˃50 1.9 
2q 7-Cl Ph t-Bu Ph 8.6±3 6.4±1.2 13.3±1.4 9.7±1.6 17.8±1.2 < 1.0 
2r 5-Br Ph t-Bu Ph N.D. N.D. ˃20 N.D. N.D. N.D. 
2s 6-Br Ph t-Bu Ph 8.5±1.8 15±1.2 >20 N.D. 20.9±1.2 1.7 
2t 6-Cl Ph-m-Cl t-Bu Ph ˃50 N.D. 18.4±1.8  20.4±1.1 N.D. N.D. 
2u H Ph t-Bu Ph-o-Cl N.D. N.D. ˃20 N.D. N.D. N.D. 
2v 5-Cl Ph t-Bu Ph-o-Cl N.D. N.D. ˃20 N.D. N.D. N.D. 
2x 7-Cl Ph t-Bu Ph-o-Cl 16.2±2.0 11.3±1.6 17.3±0.2 15.3±0.8 18.8±2.7 < 1.0 
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Table 6 – Chemical structure of spiroisoxazoline oxindoles 1 and spiropyrazoline oxindoles 2. 
 
 
 
 
 
As mentioned before, optimization of spirooxindole structure is an important part of this 
work. In a first glance, it can be noticed that the inclusion of a N-phenyl group in 
spiropyrazoline oxindoles 2c, 2f and 2l increased the activity in HCT-116 p53(+/+) more than 
2-fold comparing with the equivalent spiroisoxazoline oxindoles 1a, 1b and 1c (Table 6). This 
reassures the importance of the inclusion an extra aryl group for the activity. 
 
Our results showed that the most active compounds in HCT-116 p53(+/+) cancer cell line, 
i.e. compounds 2b, 2e, 2g, 2i, 2j, 2l, 2m and 2q, have activities between 10µM - 13µM in 
HCT-116 p53(+/+) (Table 5). To investigate if cytotoxicity was in fact mediated by activation 
of p53, compounds with IC50 values lower than 20 µM were subsequently tested in HCT-116 
cells lacking p53 (HCT-116 p53(-/-)). However, none of them was selective for p53, revealing 
that p53 related effects may not be the main contributors to cytotoxicity. 
The structure activity relationship studies (study SAR) for this family of compounds in 
HCT-116 p53(+/+) showed that change on the R3 group of a tert-butyl by a p-methoxy group 
(compound 2s versus compund 2l) leads to an increase of activity in this cell line. Halogens as 
chloro, bromo and fluoro, in the indole part are normally described with ability to occupy the 
Trp23 pocket leading to better antiproliferative activities, as is possible observe in the table 5.  
As a control of the cytotoxicity induced by the compounds towards cancer cells, we also 
analyzed the viability of CCD-18Co human normal colon fibroblasts after incubation with 
compounds 2e, 2m and 2q at the IC50 and IC80 concentrations, as previously determined for 
HCT-116 p53(+/+) (Figure 9). Notably, at the IC50 concentration, compounds 2e and 2m 
induced no cytotoxicity in normal colon fibroblasts. When the same compounds were used at 
the IC80 concentration, a decrease of approximately 20% in cell viability was observed. In 
contrast, compound 2q was cytotoxic at both equitoxic concentrations, in both cancer and 
Compound R1 R2 R3 R4 
HCT 116 p53 (+/+) 
IC50, µM 
HCT 116 p53 (-/-) 
IC50, µM 
2c 6-Cl Ph Ph Ph 16.7±0.9 17.0±0.9 
1a 6-Cl Ph Ph - 39.8±1.1 48.2±1.1 
2f 6-Br Ph Ph Ph 15.9±0.6 16.4±0.6 
1b 6-Br Ph Ph - 35.0±1.1 40.6±1.1 
2l 6-Br Ph Ph-p-O-CH3 Ph 12.8±0.7 10.0±0.6 
1c 6-Br Ph Ph-p-O-CH3 - 33.4±1.1 39.0±1.2 
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normal cell lines. These results suggest that compounds 2e and 2m are promising molecules 
to further develop as anti-tumoral agents probably with reduced off-target effects. 
 
 
 
 
 
 
Regarding human breast cancer cell lines, the most active compounds in MCF-7 cells 
(ER+/HER2-) were compounds 2e, 2f, 2k, 2l, 2o, 2q and 2s with IC50 values between 7 - 
12µM (Table 5). Conversely, compounds 2f, 2q and 2x were more active for MDA-MB-231 
triple negative cells (ER-/HER2-) with activities between 6 – 11µM (Table 5). Although, 
triple negative breast tumours are the most aggressive and the most in need for innovative 
therapeutic options, none of the compounds tested was selective for MDA-MB-231 cells. 
Nonetheless, compounds 2e (13.7 fold), 2k (8.7 fold), 2l (4.1 fold) and 2s (1.8 fold) were 
more potent in MCF-7 cells in comparison with MDA-MB-231, suggesting selectivity for 
tumour cells expressing ER. Of note, compounds 2b and 2m appear to be tissue-specific, 
since their activities are markedly different between colorectal and breast cancer cell lines 
(Table 5). 
Our SAR results have also revealed that further modification in R1 at 5-bromo, 6- and 7- 
chloro positions of indole moiety may allow the development of spiropyrazoline compounds 
with better antiproliferative activities for breast cancer cell lines.  
Finally, we tested spiropyrazoline oxindoles derivatives with IC50 values lower than 20µM 
in MCF-7 cells, in Hek-293T human embryonic kidney cells. As depicted in Table 5, 
compounds 2d and 2l showed higher potency (4.5 and 3.5 fold, respectively) towards cancer 
cells compared with Hek-293T non-tumoral cell line. Although, this cell line is of non-tumor 
origin, it is immortalized by transformation with adenovirus, which could have a significant 
impact on the results.  
 
During this thesis, additional assays were carried out to better characterize the molecular 
mechanisms involved in compounds 2e and 2m mediated effects, which will be subsequently 
presented and discussed. 
 
Figure 9 - Evaluation of cell viability in human normal colon fibroblasts (CCD-18co) following 72 h compound 
incubation 2e, 2m and 2q at equitoxic (IC50 and IC80) concentrations using the MTS metabolism assay. *p<0.05; 
**p<0.01 0.01 vs respective DMSO control. Data are mean ± S.D. of three independent experiments. 
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3.1.2. Evaluation of Cell Death 
Considering the antiproliferative activity determined for compounds 2e and 2m in HCT-
116 p53(+/+) cells, and in order to further explore the molecular mechanisms underlying the 
loss of cell viability, we decided to evaluate general cell death by lactate dehydrogenase 
(LDH) release, and apoptosis by flow cytometry and Western blot analysis. 
 
LDH release 
As depicted in Figure 10, incubation of HCT-116 p53(+/+) cells with compound 2m and 2e 
at 2xIC50 concentration, for 72h, resulted in an increase of approximately 1.5 fold in LDH 
release. Interestingly, when we incubated the compounds at the IC50 concentration, this 
induction no longer occurred, suggesting that pore formation at the cellular membrane and 
leakage of cytosolic cellular contents, such as LDH, may be a late-stage event. On the other 
hand, dysfunction of mitochondria, an organelle partially involved in MTS metabolism, 
appears to be the initial step in the death cascade. 
 
 
 
 
 
Flow Cytometry 
To evaluate if incubation of HCT-116 p53(+/+) cells with compounds 2e and 2m triggers 
apoptosis, we performed a double staining method with Annexin V-FITC and 7-
Aminoactinomycin D (7-AAD) followed by flow cytometry analysis. This assay allows to 
distinguish viable cells (FITC-/7-AAD-) from early (FITC+/7-AAD-) and late apoptotic cells 
(FITC+/7-AAD+). 
The flow cytometry results of HCT-116 p53 (+/+) cells exposed to compounds 2e and 2m 
are illustrated in Figure 11. Control cells exposed to DMSO showed intact cytoplasmic 
membrane as evidenced by the high percentage of viable cells (about 80%). When cells were 
exposed to compounds 2e and 2m at the IC50 concentration, the percentage of viable cells 
decreased to 72.9% and 71.1%, respectively. This decrease in cell viability was accompanied 
by an increase of cells in early-apoptosis. When HCT-116 p53(+/+) cells were exposed to 
compounds 2e and 2m at 2xIC50 concentration, the massive cell death observed was mainly 
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Figure 10 - Assessment of death cell induction in human colorectal cancer cell line (HCT116 p53+/+) following 
72 hours incubation with compounds 2e and 2m at equitoxic (IC50 and 2xIC50) concentration, or DMSO 
(vehicle control). Data are mean ± S.D. of three independent experiments. 
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Figure 11 - Evaluation of apoptosis in human colorectal cancer cell line (HCT116 p53(+/+)) following 72 h 
incubation with 2e and 2m at equitoxic concentrations (IC50 and 2xIC50), or DMSO (vehicle control).
**p<0.01; ***p<0.001vs DMSO. Data are mean ± S.D. of three independent experiments. 
due to cells in late-apoptosis or necrosis, suggesting that at this concentration both compounds 
may be toxic per se.  
 
 
 
 
 
 
 
 
 
Western blot Analysis 
To corroborate the flow cytometry results, we also analyzed apoptosis markers by Western 
blot. 
In theory, inhibition of p53-MDMs protein-protein interaction results in p53 stabilization 
and activation, thus leading to transcription of p53 target genes. As depicted in Figure 12, 
incubation of HCT-116 p53 (+/+) cells with compounds 2e and 2m at the IC50 concentration 
induced a mild increase in p53 total levels, and a tendency to decrease MDM2. Importantly, 
compound 2e slightly increased caspase-3 activation which is in agreement with the flow 
cytometry results and indicates that apoptosis is playing a role in 2e-mediated cytotoxic. 
Surprisingly, incubation with compound 2e did not change the cleavage of PARP, a substrate 
of caspase-3. Compound 2m did not induce caspase-3 activation or PARP cleavage. It is 
possible that 72h of compound incubation is too late to detect the differences in caspase-3 
processing and PARP cleavage. To further clarify these results, we should evaluate the same 
markers at earlier time points. 
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3.2.3. Cell Cycle Analysis 
As mentioned before, the delicate balance between cell proliferation and cell death is 
mainly orchestrated by tumour suppressors, such as p53. In fact, p53 activation is involved 
various cellular outcomes, in which apoptosis and growth arrest stand out as the most well-
known (Chapter 1). 
Since, cell death by apoptosis contributes only in part to 2e and 2m cytotoxic effects; we 
decided to further analyze cell cycle progression to better understand which mechanisms 
underlie these effects. 
HCT-116 p53(+/+) cells were exposed to compounds 2e and 2m at the respective IC50 
concentrations, for 24 h and 48 h. Cell cycle distribution was measured by flow cytometry 
using propidium iodide. As observed in Figure 13.a, 50% or 40% of cells were in the G0/G1 
phase after 24 h exposure to compounds 2m or 2e, respectively, representing a significant 
increase of 51% (p<0.01) relative to control cells. In respect to the S phase, no significant 
changes were observed. Regarding the percentage of cells in the G2/M phase, incubation with 
compound 2m resulted in a decrease of approximately 50% (p<0.01) comparing to control.  
When we analyzed cell cycle progression after 48 hour of compound exposure (Figure 
13b), the majority of cells were in G0/G1 phase, with a count of 51.6% for 2m and of 62.2% 
for 2e incubation, whereas only 42% of the control cells progressed into G0/G1 phase. 
Regarding compound 2m, about 50% of G0/G1 phase cells remained in the G0/G1 phase of 
the cell cycle (from 24 to 48 hour), emphasizing the arrest of the cell cycle. This effect was 
also noted for compound 2e. Importantly, the arrest of cells in G0/G1 was time-dependent for 
both compounds. Additionally, compound 2e significantly decreased the arrest of cells in the 
G2/M phase (2.5-fold; p<0.01) and compound 2m in the S phase (1.7-fold; p<0.01), in 
comparison to control. 
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Figure 12 – Effect of compounds 2e and 2m in p53 and MDM2 protein levels, caspase-3 activation and PARP 
cleavage. Immunoblots analyzed in total cell extracts of HCT-116p53(+/+) cell line following 72 h incubation at 
equitoxic IC50 concentration, or DMSO (vehicle control). Blots were normalized with ponceau staining as 
control. Cropped blot to exclude two other compounds used from other spirooxindole family.Data are mean ± 
S.E.M. of two independent experiments. 
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The arrest of cells in the G0/G1 phase may be induced to allow the repair of damaged 
DNA, or to inhibit cell growth84,85. These results suggest that both induction of apoptosis and 
cell cycle arrest are important mechanisms underlying 2e and 2m effects in HCT-116 p53(+/+) 
cells.  
 
3.2.4. Combination of Spiropyrazoline Oxindoles and Chemotherapeutic Drugs 
Drug combination is widely used to achieve efficacy when treating several types of cancer. 
The main goal is to achieve a synergistic therapeutic effect accompanied by decreased 
toxicity, and reduced drug resistance. Taking this into account, studying the effect of a 
combination of drugs compared to the single agent is of particular interest86,87. 
We determined the IC50 values of commercial chemotherapeutic drug 5-FU prior to 
combined therapy assay. 5-FU acts as a thymidylate synthase inhibitor (blocking DNA 
replication) 88,89. The compound in test has the ability to arrest cell cycle in the G0/G1 phase 
and in a less extent to induce apoptosis. 
Figure 13 - Evaluation of cell cycle progression in human colorectal cancer cell line (HCT116 p53+/+) following 
(a) 24 hours and (b) 48 hours incubation with compounds 2e and 2m at equitoxic (IC50) concentration, or DMSO 
(vehicle control). **p<0.01 vs respective DMSO control. Data are mean ± S.D. of three independent 
experiments. 
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Cell viability of HCT-116 p53(+/+) subjected to combined therapies and coefficient drug 
interaction were calculated applying formula (3) of Chapter 6. As observed in Figure 14, 
combination of 5-FU at IC10 with 2e at IC20 concentration, resulted in the best synergistic 
effect (CDI<1) (p<0.001). Nevertheless, when 2e was used at IC10 (p<0.001) and IC50 
(p<0.01) the synergism was still significant. In contrast, combination of 5-FU at IC50 
concentration with compound 2e at IC10 concentration resulted in an antagonic effect 
(CDI>1). Overall, the results suggest that by combining different drugs at concentrations 
below the IC50 we can achieve better results and possibly with less side effects. However, 
more studies should be performed to further address this question. 
 
 
 
 
 
 
 
 
3.2.5. Evaluation of Compounds’ Ability to block the p53-MDM2 Interaction 
To verify if this family of compounds can inhibit the p53–MDM2 interaction, a 
bimolecular fluorescence complementation assay (BiFC) was used. BiFC is a simple and 
robust assay that allows the direct visualization and quantification of p53–MDM2 interaction 
in live cells71,90. This assay is based on the reconstitution of an intact fluorescent protein when 
two complementary non-fluorescent fragments are brought together by a pair of interacting 
proteins (Figure 15). 
 
 
 
 
 
Figure 14 - Coefficient drug interaction (CDI) analysis of compound 2e with 5-Fluorouracil. HCT-116 cells
were exposed to compounds for 72h and cell viability was evaluated using the MTS metabolism assay. 
Threshold- CDI value threshold (CDI=1). 2eIC10=9.5µM; 2eIC20=10.7 µM; 2eIC50=13.0 µM and 5-FUIC10=1.7
µM; 5-FUIC20=2.2 µM; 5-FUIC50=3.2 µM. **p<0.01; ***p<0.001. Data are mean ± S.E.M. of five independent 
experiments. 
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By applying this methodology, it was demonstrated that compounds 2e and 2m at 20µM, 
can inhibit p53-MDM2 interaction in the same level as half concentration of nutlin-3a (10µM) 
(p<0.05 and p<0.01, respectively) (Figure 16). This assay, allows the quantification of p53-
MDM2 interaction in live cells by flow cytometry, given that, the observed decrease of 
fluorescence represents the ability of the compounds to decrease p53-MDM2 interaction.  
 
 
 
 
 
 
 
3.3. BIOLOGICAL EVALUATION - GLIOMA CANCER CELL LINE 
Glioblastoma multiforme (GBM) is the most common primary malignancy in the brain. 
TP53 mutation affects approximately 28% of primary glioblastoma cases and 65% of 
secondary glioblastomas, making it the most common molecular abnormality in glioma. 
Recent studies showed that alterations of p53 pathway in GBM included MDM2 
amplification (11%), and MDM4 amplification (4 %), in addition to mutations of p53 itself. 
Taking into account the results using this library of spiropyrazoline oxindoles in two other 
types of cancer (breast and colorectal cancer), we decided to further test these molecules in a 
mouse glioma cell line (GL-261). 
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Figure 16 - Compound 2e and 2m decreases p53-MDM2 interaction by BiFC. HCT116 p53(–/–) cells were co-
transfected for 24 hours. *p<0.05; **p<0.01. Data are mean ± S.D. of three independent experiments. 
Figure 15 - The proteins of interest are fused to non-fluorescent fragments (F1 and F2) of a fluorescent reporter 
protein. When the proteins of interest interact, the non-fluorescent halves get close enough to fold together and 
reconstruct the functional fluorophore. When inhibition of p53-MMDM2 interaction exist by an inhibitor 
molecule (I), occurs a reduced signal.  
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The library of spiropyrazolines was screened in GL-261 cells that present a TP53 gene 
mutation91,92. Importantly, compound 2x exhibited moderate antiproliferative activity with an 
IC50 value below 20µM. Therefore, to evaluate its effects in non-tumoral control cells, we 
further tested 2x at IC50 and IC98 equitoxic concentrations in primary mouse astroglial 
cultures. 
As observed in Figure 17, incubation of primary astroglial cells with compound 2x reduced 
cell viability in approximately 20% at the IC50 concentration, and 50% at the IC98 
concentration, suggesting that compound induced non-cytotoxicity in normal cells and  is 
promising molecule to further develop as anti-tumoural agents with reduced off-target effects.  
 
 
 
 
 
 
During this thesis, additional assays were carried out to better characterize the molecular 
mechanisms involved in compound 2x mediated effects, which will be subsequently presented 
and discussed. 
 
3.3.1. Evaluation of Cell Death 
Considering the antiproliferative activity determined for compound 2x in GL-261 cells, 
and in order to further explore the molecular mechanisms underlying the loss of cell viability, 
we decided to evaluate apoptosis by flow cytometry. 
Regarding GL-261 cells, the results demonstrate that apoptosis is not the death mechanism 
induced by compound 2x (Figure 18), since no significant changes were observed in the 7-
AAD/Annexin V assay. Therefore, alternative mechanisms, such as cell growth inhibition93, 
should be investigated to better understand the mode of action of this compound. 
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Figure 17 - Evaluation of cell viability in primary mouse astroglial cell culture following 72 h incubation with 
compound 2x at equitoxic (IC50 and IC98) concentrations using the MTS metabolism assay. Data are mean ± S.D. 
of three independent experiments. 
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3.3.2. Cell Cycle Analysis 
GL-261 cells were exposed to compound 2x, at the respective IC50 concentrations, for 24 h 
and 48 h. Cell cycle distribution was measured by flow cytometry using propidium iodide. As 
depicted in Figure 19, exposure of GL-261 cells to compound 2x did not induce any changes 
in the cell cycle profile as compared with vehicle control. Therefore, we did not proceed the 
studies in this cell line. 
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Figure 18 - Evaluation of apoptosis in GL261 cells, following 72 h incubation with compound 2x at equitoxic 
(IC50 and twice of IC50) concentration, or DMSO (vehicle control). Data are mean ± S.D. of two independent 
experiments. 
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3.4. COMPOUND STABILITY STUDIES 
 The stability of a compound in PBS is an important parameter to assure that the compound 
effect is truly achieved by the molecule itself and not by subsequent derivatives of its 
degradation.  Therefore, the chemical stability of compounds 2e, 2m and 2x was evaluated in 
pH 7.4 phosphate buffer (PBS) at 37 ºC. Importantly, compounds 2e and 2m were stable in 
PBS for 72 h (Table 7). This property is still significant for future therapeutic applications. 
 
Table 5 - Stability of spiropyrazoline oxindole compounds (2e, 2m and 2x) in PBS. Data of three independent 
experiments. 
 
 
 
 
 
 
Compounds Incubation time (hours) 
Original peak Degraded peak 
% abs % abs 
2m 
0 100,0 12,783 0,0 - 
72 89,44 12,947 10,56 5,671 
2e 
0 100,0 12,083 0,0 - 
72 59,39 11,907 40,61 5,240 
2x 
0 100,0 12,083 0,0 - 
72 59,39 11,907 40,61 5,240 
Figure 19 - Evaluation of cell cycle progression in GL261 cells, following (a) 24 hours and (b) 48 hours
incubation with compound 2x at equitoxic (IC50) concentration, or DMSO (vehicle control). Data are mean ± 
S.D. of three independent experiments. 
G0/G1 
S G2/M 
G0/G1 G0/G1 
S 
S 
G2/M G2/M 
G2/M S 
G0/G1 
53 
 
3.5. FINAL CONSIDERATIONS 
A library of twenty-three spiropyrazoline oxindoles was designed and synthesized. 
Compound screening in HCT-116 p53(+/+) cell line revealed that seven derivatives displayed 
potency below 13μM. However, a lack of selectivity between the isogenic pair of cell lines 
HCT-116 p53(+/+) and p53(-/-) was observed for all compounds. Nevertheless, we demonstrated 
that spiropyrazolines oxindoles 2e and 2m were capable of disrupting the p53-MDM2 
interaction. Compounds 2e and 2m also promoted induction of apoptosis and cell cycle arrest 
in G0/G1 phase, and increased p53 expression levels in HCT-116 p53(+/+) cell line. 
Importantly, no cytotoxic effects were detected in human normal colon fibroblasts (CCD-18-
Co cell line). In addition, four spiropyrazoline oxindoles (2e, 2k, 2l and 2s) showed selectivity 
for tumour cells expressing ER, more specifically for MCF-7 breast cancer cell lines. 
All compounds were also screened in GL-261 glioma cell line, with only one compound 
presenting potency below 20 μM. However, this compound failed in inducing both apoptosis 
and cell cycle arrest. 
Finally, three compounds of this library were stable in PBS (pH 7.4) for 72 h. 
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Chapter 4 
 
 
 
 
 
 
SPIROTRYAZOLINE OXINDOLES: 
MECHANISM OF ACTION 
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A library of spirotryazoline oxindoles was previously studied in our research group as 
potential anti-cancer agents. This family presented good antiproliferative activity for the 
MCF-7 breast cancer cell line, with some compounds showing selectivity towards the MDA-
MB-231 triple negative breast cancer cell line.  In addition, these compounds were capable of 
disrupting the p53-MDM2 interaction as observed using a live-cell bimolecular fluorescence 
complementation assay in a human colorectal cancer cell line, and were also selective toward 
tumoural cell lines versus non-tumoural Hek-293T cells. These compounds also induced cell 
death by apoptosis as observed by the dose-dependent increase of caspase-3 and -7 and PARP 
cleavage. Finally, good stability in plasma and susceptibility towards NADPH-dependent rat 
microsomal enzymes were observed94. 
Now, we further explored the molecular mechanisms of action of the most promising 
spirotryazoline oxindoles developed, compounds 7f, 7h, 7z, to be used as potential anti-
tumoural agents. 
 
 
 
 
 
 
 
4.1. BIOLOGICAL STUDIES – COLORECTAL CANCER CELL LINE 
4.1.1. Evaluation of Cell Death 
Flow Cytometry 
Among the library of spirotryazoline oxindoles previously described (manuscript in 
preparation), compounds 7f and 7z were the most promising as potential antitumoral agents 
and therefore they were selected to further explore their mechanism of action.  
Cell death by apoptosis was evaluated by flow cytometry using a biparametric analysis 
with 7-AAD and Annexin-V-FITC in HCT-116 p53(+/+) cells. 
As depicted in Figure 20, approximately 80% of control cells exposed to DMSO were 
viable. Incubation of cells with compounds 7f and 7z at the IC50 concentration slightly 
induced cell death in approximately 7%. However, if we look at the subpopulation of cells 
exhibiting hallmarks of early apoptosis (FITC+/7-AAD-), a significant increase of 3.1-fold 
(p<0.01) and 2.8-fold (p<0.05) was observed for compounds 7f and 7z, respectively. These 
results become more interesting when we incubated the same compounds at 2xIC50 
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Scheme 4 - Chemical structure of spirotryazoline oxindoles 7f, 7h and 7z.  
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concentration. Here, we observed a robust dose-dependent response. When we incubated the 
same compounds at 2xIC50 concentration, the percentage of viable cells significantly 
decreased from 77.5% to 65.8% and 43.9% after incubation with 7f and 7z, respectively, 
corresponding to a 1.2-fold (p<0.05) and 1.8-fold (p<0.01) decrease, respectively. More 
importantly, this decrease of cell viability was accompanied by a significant increase of cells 
dying exclusively by apoptosis (FITC+/7-AAD+) (7f, 2.5-fold, p<0.01 and 7z, 4.4-fold, 
p<0.001) in comparison with DMSO vehicle control.   
 
 
Western blot Analysis 
To corroborate the flow cytometry results, we further analyzed apoptosis markers by 
Western blot using total extracts of HCT-116 p53(+/+) cells treated with compounds 7f and 7z. 
As shown in Figure 21, compounds 7f and 7z significantly decreased MDM2 protein 
expression levels (p<0.05), while a tendency to increase p53 was observed for both 
compounds.  Regarding caspase-3 activation and PARP cleavage, the results were somehow 
contradictory, since we could not detect an increase of caspase-3 activation with both 
compounds, but we still detected an increase of PARP cleavage, at least for compound 7f. 
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Figure 20 - Evaluation of apoptosis in human colorectal cancer cell line (HCT-116 p53+/+) following 72 h 
incubation with compounds 7f and 7z at equitoxic (IC50 and 2xIC50) concentrations, or DMSO (vehicle control).
*p<0.05; **p<0.01; ***p<0.001 vs DMSO. Data are mean ± S.D. of three independent experiments. 
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4.1.2. Cell Cycle Analysis 
In addition to cell death, growth inhibition may also play an important role in the loss of 
cell viability. In fact, several cytostatic agents show a marked growth inhibitory effect on a 
variety of tumors where growth arrest is followed by the activation of apoptotic pathways and 
cell death. In this regard, cell cycle analysis may help to understand whether the loss of 
viability observed upon cell treatment with compounds 7f and 7z is also mediated by changes 
in the cell cycle progression. 
HCT-116 p53(+/+) cells were exposed to compounds 7f and 7z at the IC50 concentration for 
24 and 48 hours.  
At 24 hours of exposure, compound 7f increased the number of cells in the G0/G1 phase in 
about 50% (p<0.01) (Figure 22). Both 7f and 7z induced a significant decrease of 
approximately 10% (p<0.05) and 22% (p<0.01) of cells in the G2/M phase, respectively. 
After 48 hours, approximately 54% of the cells treated with both 7f and 7z were in the 
G0/G1 phase whereas only 42% of the control cells progressed into this phase. Moreover, 
compounds 7f and 7z decreased the percentage of cells in G2/M phase in about 15% and 
10%, respectively (p<0.05). 
 
 
 
 
Figure 21 - Effect of compounds 7f and 7z in p53 and MDM2 protein levels, caspase-3 activation and PARP 
cleavage. Immunoblots analyzed in total cell extracts of HCT-116 cell line following 72 h incubation at 
equitoxic IC50 concentration, or DMSO (vehicle control). Blots were normalized with ponceau staining as 
control. Cropped blot to exclude two other compounds used from other spirooxindole family. *p<0.05 vs
DMSO. Data are mean ± S.E.M. of two independent experiments. 
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4.1.3. Cytotoxicity evaluation in human normal colon fibroblasts 
To discard the potential cytotoxic effects of compounds 7f and 7z in non-tumoral cells, we 
analyzed the viability of human normal colon fibroblasts after treatment with the two 
compounds, at the IC50 and IC80 equitoxic concentrations, previously determined for HCT-
116 p53(+/+) cells. As observed in Figure 23, treatment with 7f and 7z at the IC50 concentration 
did not affect cell viability. When we used higher concentrations, we could detect a reduction 
of approximately 40% in cell viability, which is still far below of the values obtained for the 
HCT-116 p53(+/+) cell line. 
 
The absence of cytotoxic effects induced by compounds 7f and 7z in human normal colon 
fibroblast cells is an advantage for using these compounds as potential therapeutic agents.  
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Figure 22 - Evaluation of cell cycle progression in human colorectal cancer cell line (HCT116 p53+/+) 
following (a) 24 hours and (b) 48 hours incubation with compounds 7f and 7z at equitoxic (IC50) concentration, 
or DMSO (vehicle control). *p<0.05; **p<0.01 vs respective DMSO (control). Data are mean ± S.D. of three 
independent experiments. 
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4.2. BIOLOGICAL STUDIES – BREAST CANCER CELL LINE 
4.2.1. Evaluation of Cell Death 
Flow Cytometry 
MDA-MB-231 cell line represents the triple negative cancer, one of the most aggressive 
and most in need of innovative therapeutic. One compound of the library in study, showed the 
best antiproliferative activity toward MDA-MB-231 breast cancer cell line in comparison 
with other cancer cells lines94 (HCT-116 p53(+/+) and MCF-7).  
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Figure 22 – Evaluation of cell viability in human normal colon fibroblasts (CCD-18co) following 72 hours
incubation with compounds 7f and 7z at equitoxic (IC50 and IC80) concentrations using the MTS metabolism 
assay. Data are mean ± S.D. of two independent experiments. 
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Figure 23 - Evaluation of apoptosis in human breast cancer cell line (MDA-MB-231) following 72 h incubation 
with compound 7h at equitoxic (IC50 and 2x IC50) concentrations, or DMSO (vehicle control). *p<0.05; 
**p<0.01 vs respective DMSO (control) Data are mean ± S.D. of three independent experiments. 
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These results shown in Figure 24 reveal that compound 7h does not induce apoptosis in 
this cell line, thus suggesting that the antiproliferative activity observed for this compound 
should be dependent of other mechanisms rather than apoptosis. The cytostatic mechanism93 
that lead to a cell growth/proliferation inhibition can be one of these mechanisms. 
 
Caspase-3/7Activity Analysis 
To corroborate the flow cytometry results, we also analyzed caspase-3/7 activity in MDA-
MB-231 cells using a luminescent assay. In contrast to what we observed by flow cytometry, 
here we could detect a significant increase of caspase-3/7 activity (p<0.01) after incubation of 
cells with compound 7h (Figure 25). Therefore, other experiments should be performed to 
better clarify the role of apoptosis in 7h-mediated effects in this cell line. 
 
 
 
 
 
4.2.2. Cell Cycle Analysis 
The cell cycle study allows understanding whether the loss of viability through the 
compound 7h could be preceded by changes in the cell cycle progression. 
MDA-MB-231 cell line was exposed to the IC50 of compounds over 24 hours and 48 hours. 
The results observed in Figure 26, show a small cell cycle arrest in G2/M, when we 
compare the MDA-MB-231 cells exposed to compound 7h with the control group DMSO, 
over the exposure time (24 to 48 hours of exposure). 
 
Thus, the cell cycle arrest in G2/M may indicate a growth inhibition in cells but it is not 
necessary to happen an induction of cell death, and this can happen through the mechanisms 
associated with p53 in cell homeostasis84,85. 
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Figure 24 - Compound 7h induces activation of caspase-3 and -7 after 48 hours of exposition.  Caspase-3/7 
activity was measured using the Caspase-Glo 3/7 assay (Promega) in total cell extracts of MDA-MB-231 cell 
line. **p<0.01 vs DMSO. Data are mean ± S.D. of two independent experiments. 
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4.3. FINAL CONSIDERATIONS 
The mechanism of action of three spirotryazoline oxindoles as potential anti-cancer agents 
was studied in more detail. Compounds 7f and 7z were not cytotoxic in normal cells, while 
induced apoptosis and cell cycle arrest in G0/G1 phase in the HCT-116 colorectal cell line. 
Additionally, 7f and 7z slightly induced p53 and decreased MDM2 expression. These changes 
in p53 and MDM2 expression levels, confirm the ability of spirotryazoline oxindoles to 
modulate p53-MDM2 interaction. Moreover, 48 hours of cell exposure to compound 7h also 
promoted cell cycle arrest in G2/M and a significant increase of caspase-3 and -7 activities, 
which may indicate that 72 hours was too late to observe other apoptosis-related changes, 
such as caspase-3 processing and PARP cleavage.  
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Figure 25 - Evaluation of cell cycle progression in human breast cancer cell line (MDA-MB-231 following (a) 
24 hours and (b) 48 hours incubation with compound 7h at equitoxic (IC50) concentration, or DMSO (vehicle 
control). *p<0.05 vs respective DMSO control. Data are mean ± S.D. of two independent experiments. 
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The main goal of this master thesis was the development and optimization of 
spirooxindoles with different 5-membered rings as new anticancer agents. This thesis was 
divided into two major goals. 
The first, presented in chapter three, includes the development and optimization of a 
library of spiropyrazoline oxindoles (synthesized by 1,3-dipolar cycloaddition reaction), and 
the biological evaluation of these compounds as potential anticancer agents. 
More specifically, chapter three focused on the synthesis of twenty three spiropyrazoline 
oxindoles, their biological evaluation and stability assessment. In this chapter, spiropyrazoline 
oxindoles containing different phenyl groups at position 4’, presented an increase in the 
antiproliferative activity, compared with the ones obtained for the equivalent spiroisoxazoline 
oxindoles.  
Compounds 2b, 2e, 2g, 2i, 2j, 2l, 2m and 2q showed antiproliferative activities between 10 
μM and 13 μM for HCT-116 p53(+/+) cell line, but for all compounds no significant differences 
were observed when using the isogenic cell line lacking p53. Subsequently, seven other 
compounds (2e, 2f, 2k, 2l, 2o, 2q and 2s) showed antiproliferative activities between 7μM 
and 12μM for MCF-7 breast cancer cell line, and three compounds (2f, 2q and 2x) showed 
antiproliferative activities between 6µM and 11µM for MDA-MB-231 cell line. MDA-MB-
231 cell line represents the triple negative cancer, one of the most aggressive and the most in 
need of innovative therapeutic. In addition, six compounds showed selectivity toward cancer 
cell lines over Hek-293T with non-tumoral origin. Despite the lack of selectivity for p53 
observed in the majority of compounds tested in HCT-116 cell lines, they were more active 
for breast cancer cell lines comparing with colorectal cancer cell lines. 
Moreover, two compounds (2e and 2m) revealed to be potentially non-cytotoxic to the 
normal human colon fibroblasts, which further show the therapeutic potential of these 
compounds. For these same compounds, a dose-response and an increase of late apoptosis 
hallmarks were found in HCT-116 cell line. The relevance of such noteworthy evidence 
comes from the fact that a higher proportion of cells in latter stages of apoptosis are indicative 
of the compound’s ability to induce apoptosis faster and to induce a quicker mechanism of 
action. These compounds also exhibit a dose response to an increase of time exposure and the 
arrest of the cells in G0/G1. This arrest can be evidence of a potential p53’s action. Thus, the 
cell cycle arrest in G0/G1 may indicate either a stop for the repair of the damaged DNA or a 
growth in the inhibition of cells. Additionally, the ability to induce cell death in HCT-116 
cells by the compounds was confirmed by LDH assay. The apparent inhibition of p53-MDM´ 
proteins interaction was shown by p53 activation in cancer cell lines. This can thus lead an 
induction of target proteins of p53, such as activation of caspase-3 and a block of MDM2 
function with a decrease of proteins expression levels. Additionally, the bimolecular 
fluorescence complementation (BiFC) assay corroborated the potential inhibition of the 
MDM2-p53 complex by spiropyrazoline oxindoles. Moreover, combined therapy studies were 
performed demonstrating a synergistic effect with a chemotherapeutic agent and potentiating 
the use of this family of compounds to a better therapy with possible minor side effects 
associated. 
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This family of compounds was also assessed in GL-261 cell line where it has not showed a 
dose-response effect and no apparent induction of apoptosis. Moreover, it has not showed an 
arrestment of the cell cycle. This can be explained through a cell growth/proliferation 
inhibition, known as cytostatic mechanism. These compounds exhibit a good stability in PBS.  
Spiropyrazoline oxindoles compounds have different characteristics indicative of apoptosis 
induction for different cancer types. Advantageous characteristics are presented such as the 
non cytotoxicity in human normal cells; the inhibition of the MDM2-p53 complex and the 
potential use of these compounds in a combined therapy strategy with currently used 
chemotherapeutic agent (5-Fluorouracil).  
 
Additionally, further testing should be performed, as the study of combination therapy with 
other chemotherapeutic agents (Oxaliplatin and Irinotecan) and subsequent verification of 
these compounds in normal cells. Moreover, for the best molecules should be made studies 
about cyclin expression involved in the cell cycle arrest, in order to better understand the 
effects of this family of compounds, should be performed. 
 
The other main goal of this master thesis was to study the effect on biological activity of 
replacing, in the spirooxindole structure, a carbon at position 4´ (pyrazoline ring) by nitrogen 
(tryazoline ring). 
Three compounds were evaluated as potential anticancer agents. Two were non-cytotoxic 
in normal human colon fibroblasts. This can be a potential favourable point, for further 
development of these compounds as therapeutic drugs. For these same compounds, a dose-
response and an increase of late apoptosis hallmarks were found in HCT-116 p53(+/+) cell line. 
The relevance of such noteworthy evidence comes from the fact that a higher proportion of 
cells in latter stages of apoptosis are indicative of the compound’s ability to induce apoptosis 
faster and to induce a quicker mechanism of action. Compound 7f presents a dose-response 
depending on the exposure time and presents the arrest of the cells in G0/G1 phase. This 
arrest can evidence a potential action of p53. However, compound 7z presents a progression 
on the cell cycle followed by an increase of the compound’s concentration. The ability to 
inhibit p53-MDM´ proteins interaction was shown by an increase of p53 and MDM2 
expression levels. 
This family of compounds was also assessed in MDA-MB-231 cell line. Compound 7h did 
not show a dose-response effect and no apparent induction of apoptosis. Moreover, cell cycle 
arrest in G2/M may indicates induction of growth cells inhibition. Activation of caspase 3/7 
by compound 7h was observed. This can indicate that the compound can be involved in an 
apoptotic process, since caspase-3 and -7 are reliable markers of apoptosis. 
These data indicates that spirotryazoline oxindoles have different characteristics indicative 
of apoptosis induction for different cancer types. Advantageous characteristics are presented 
such as non cytotoxicity in human normal cells. 
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As all, the results were obtained in vitro. As pharmacokinetics and pharmacodynamics 
properties of compounds can be intricately different in vivo, it is now required to study the 
most promising compounds in vivo. 
In conclusion, the potential of two spirooxindoles libraries as anticancer agents and 
inhibitors of the p53-MDM2 interaction was demonstrated. In particular, it was shown that 
these new molecules have different abilities, resulting from the inhibition of p53-MDM2 
interaction, such as the ability to induction of apoptosis and cell cycle arrest, possible 
activation of caspase-3, increase of p53 and MDM2 expression levels in HCT-116 p53(+/+) cell 
line. Moreover, it was shown that they are non-cytotoxic to cells health, being selective for 
cancer cells over normal cells.  
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6.1. CHEMISTRY  
All chemical and solvents were obtained from commercial suppliers and were used without 
further purification. When used as reaction solvents, CH2Cl2 was dried over CaCl2 and 
distilled; THF was distilled from sodiumbenzophenone system. Et3N was dried over KOH, 
distilled and stored with molecular sieves. Thin layer chromatography was performed using 
Merck Silica Gel 60 F254 aluminium plates and visualized by UV light. Flash column 
chromatography was performed on Merck Silica Gel (200-400 mesh ASTM). Preparative 
TLC was performed on Merck Silica Gel 60 GF254 over glass plates. 
1H and 13C NMR spectra were recorded on a Bruker 400 Ultra-Shield at 400 MHz (1H 
NMR) and 101 MHz (13C NMR) or on a Bruker 300 Ultra-Shield at 300 MHz (1H NMR) and 
75 MHz (13C NMR). 1H and 13C chemical shifts (δ) are expressed in parts per million (ppm) 
using the solvent as internal reference, and proton coupling constants (J) in hertz (Hz). 1H 
spectral data are reported as follows: chemical shift, multiplicity (s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet; dd, doublet of doublets; dt, doublet of triplets, and br, 
broadened), coupling constant, and integration. 
The infrared spectra were collected on a Shimadzu FTIR Affinity-1 spectrophotometer. 
The spectra were determined using KBr disks. Only the most significant absorption bands are 
reported. 
Spirotriazoline oxindoles were obtained by 1,3-dipolar cycloaddition between 3-imino-
indolin-2-ones and nitrile imines generated in situ by dehydrohalogenation of hydrazonyl 
chlorides. They were synthesized in good yields (60-95 %), as reported94. 
Elemental analysis (C, H, and N) were performed in a Liquid Chromatography and Mass 
Spectrometry Laboratory, Faculty of Pharmacy of Lisbon University. 
 
6.1.1. General Procedure for the Synthesis of 2-Indolinones 
A reaction mixture of the proper substituted indolin-2-ones 6, aldehyde, and piperidine in 
ethanol was refluxed for 3-5 hours, under nitrogen atmosphere. After, the mixture was cooled 
and put on ice, where the product precipitated. The product was filtered in vacuum with cold 
ethanol70,76–79. Finally, the product was placed in the vacuum desiccators to give the expected 
compound. The indolin-2-ones 3 were sometimes generated through substituted isatin in the 
presence of hydrazine monohydrate and ethylene glycerol, under reflux80. 
 
6.1.2. General Procedure for the Synthesis of Hydrazonyl Chlorides 
Method A: 
Triethylamine was added to a mix of phenylhydrazine derivative in dry THF at 0°C, under 
inert atmosphere. After stirring for 10 minutes, trimethylacetyl chloride was added dropwise. 
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The mixtures were then left to stir under inert atmosphere at room temperature. The reactions 
mixtures were quenched with water (H2O) (1x of solvent volume). The phases were separated 
and the aqueous phase was extracted twice (2x of solvent volume) with Ethyl Acetate 
(EtOAc). All organic phases were extracted thrice with Sodium Bicarbonate (NaHCO3) (2x of 
solvent volume) and dried over with Sodium Sulfate (Na2SO4). The product was dried on the 
rotary evaporator to afford the corresponding hydrazone. Then, triphenylphosphine dissolved 
in Acetonitrile was added to the corresponding hydrazone. After stirring for 30 minutes of the 
addition of triphenylphosphine, carbon tetrachloride was added to the reaction, at room 
temperature under inert atmosphere. The solvent was removed in rotary evaporator. Then, the 
crude was purified by flash chromatography on silica gel using an indicated gradient of eluent 
(n-hexane/EtOAc) for each compound, to afford the final hydrazonyl chloride (4b, 4d and 
4e)75,81. 
 
Method B: 
A mixture of phenylhydrazine derivative, and benzaldehyde derivative in aqueous ethanol 
20% was stirred at room temperature in the dark for 2-3 hours. The precipitate formed was 
filtered and washed with aqueous ethanol 20%. Then, to NCS in CH2Cl2 at 0°C was added 
dropwise dimethyl sulfide over 5 minutes. After stirring for 15 minutes, the reaction was 
further cooled to –78°C. Subsequently, resulting hydrazone dissolved in CH2Cl2, was added. 
The reaction was stirred at –78°C for 1h, and then slowly allowed to warm to room 
temperature over 3 hours. The reaction was quenched by addition of cold water. The organic 
layer was then washed with brine (1x), saturated sodium sulfite aqueous solution (2x), and 
water. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated to 
afford the corresponding hydrazonyl chloride (4a and 4c) 82. 
 
6.1.3. General Procedure for the Synthesis of 2',4'-Dihydrospiro[Indoline-3,3'-
[Pyrazol]-2-ones 
Triethylamine/N,N- diisopropylethylamine was added dropwise to a mixture of indolin-2-
one 3 derivative  and hydrazonyl chloride 4 derivative in dry CH2Cl2 under nitrogen 
atmosphere. The reaction mixture was quenched with water (H2O). The phases were separated 
and the aqueous phase was extracted with Ethyl Acetate (3xEtOAc). The combined organic 
extracts were dried over anhydrous Na2SO4 and the product was dried on the rotary 
evaporator. The residue was purified by flash chromatography on silica to afford the final 
spiropyrazoline oxindole compound 270. 
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2',4',5'-triphenyl-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-2-
one (2a) 
Following the general procedure, to a solution of 3a (0.075g, 
0.34mmol) in CH2Cl2 (2ml) was added 4a (0.12g, 0.51mmol, 1.5 eq) 
and triethylamine (0.14 ml, 1.02 mmol, 3 eq). Reaction time: 22h. 
The compound was purified by flash chromatography (eluent: 
EtOAc/n-Hexane 1:3) and then recrystallized in diethyl ether to afford compound 2a as a light 
yellow solid (0.1g, 0.3mmol, 78.0%). 
IR (KBr): 3198 (NH), 1719 (C=O), 1618 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H, NH), 7.71 – 7.65 (m, 2H, H), 7.31 – 7.24 (m, 
3H, H), 7.16 – 7.06 (m, 5H, H), 7.03 (t, J = 7.7 Hz, 1H, H), 6.94 (d, J = 7.9 Hz, 4H, H), 6.81 
(t, J = 7.3 Hz, 1H, H), 6.76 (d, J = 7.8 Hz, 1H, H), 6.55 (t, J = 7.6 Hz, 1H, H), 6.35 (d, J = 7.5 
Hz, 1H, H), 5.16 (s, 1H, H-4). 
13C NMR (101 MHz, CDCl3) δ 178.50 (C=O), 148.93 (C=N), 144.33 (Cq), 140.25 (Cq), 
134.78 (Cq), 131.81 (Cq), 129.48 (CH), 129.29 (CH), 129.03 (CH), 128.76 (CH), 128.66 
(CH), 128.47 (CH), 128.02 (CH), 126.95 (CH), 126.54 (CH), 125.65 (Cq), 122.40 (CH), 
121.08 (CH), 115.43 (CH), 110.63 (CH), 76.84 (Cspiro), 62.67 (CH-4). Anal. Calc. for 
C28H21N3O: C 80.94, H 5.09, N 10.11, Found: C 80.88, H 5.34, N 9.95. 
 
 5-chloro-2',4',5'-triphenyl-2',4'-dihydrospiro[indoline-3,3'-
pyrazol]-2-one (2b) 
Following the general procedure, to a solution of 3b (0.075g, 
0.29mmol) in CH2Cl2 (2ml) was added 4a (0.10g, 0.44mmol, 1.5 
eq) and triethylamine (0.12 ml, 0.87 mmol, 3 eq). Reaction time: 
16h30min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:4) and then recrystallized in dichloromethane to afford compound 
2b as a light yellow solid (0.1g, 0.2mmol, 81.8%). 
IR (KBr): 3171 (NH), 1730 (C=O), 1595 (C=N) cm-1. 
1H NMR (400 MHz, DMSO.d6) δ 10.11 (s, 1H, NH), 7.63 – 7.53 (m, 2H, H), 7.19 (d, J = 
5.2 Hz, 3H, H), 7.15 – 7.07 (m, 3H, H), 7.03 (t, J = 8.0 Hz, 2H, H), 6.94 (dd, J = 8.3, 2.0 Hz, 
1H, H), 6.86 (dd, J = 13.3, 5.6 Hz, 4H, H), 6.74 (t, J = 7.3 Hz, 1H, H), 6.68 (d, J = 8.3 Hz, 1H, 
H), 6.18 (d, J = 1.6 Hz, 1H, H), 5.06 (s, 1H, H-4). 
13C NMR (101 MHz, DMSO.d6) δ 177.03 (C=O), 148.17 (C=N), 143.57 (Cq), 139.06 
(Cq), 133.81 (Cq), 130.98 (Cq), 128.68 (C-Cl), 128.43 (CH), 128.17 (CH), 127.84 (CH), 
127.65 (CH), 126.83 (CH), 126.67 (CH), 126.26 (CH), 125.99 (Cq), 120.46 (CH), 114.65 
(CH), 110.84 (CH), 76.35 (Cspiro), 62.08 (CH-4). Anal. Calc. for C28H20ClN3O.0.5CH2Cl2: C 
69.63, H 4.31, N 8.55, Found: C 69.19, H 4.31, N 8.55. 
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 6-chloro-2',4',5'-triphenyl-2',4'-dihydrospiro[indoline-3,3'-
pyrazol]-2-one (2c) 
Following the general procedure, to a solution of 3c (0.075g, 
0.29mmol) in CH2Cl2 (2ml) was added 4a (0.098g, 0.41mmol, 1.5 
eq) and triethylamine (0.12 ml, 0.87 mmol, 3 eq). Reaction time: 
21h. The compound was purified by flash chromatography (eluent: 
EtOAc/n-Hexane 1:4) and then recrystallized in dichloromethane to afford compound 2c as a 
light yellow solid (0.1g, 0.2mmol, 83.1%). 
IR (KBr): 3171 (NH), 1722 (C=O), 1611 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 8.95 (s, 1H, NH), 7.68 (d, J = 5.4 Hz, 2H), 7.29 (d, J = 5.1 
Hz, 3H), 7.18 (s, 3H), 7.12 (t, J = 7.7 Hz, 2H), 6.94 (t, J = 8.5 Hz, 4H), 6.85 (t, J = 7.0 Hz, 
1H), 6.78 (s, 1H), 6.55 (d, J = 8.1 Hz, 1H, H), 6.23 (d, J = 8.1 Hz, 1H, H), 5.11 (s, 1H, H-4). 
13C NMR (101 MHz, CDCl3) δ 178.62 (C=O), 149.19 (C=N), 144.22 (Cq), 141.12 (Cq), 
135.39 (C-Cl), 134.44 (Cq), 131.56 (Cq), 129.17 (CH), 128.99 (CH), 128.93 (CH), 128.56 
(CH), 128.34 (CH), 127.39 (CH), 126.97 (CH), 124.09 (Cq), 122.65 (CH), 121.48 (CH), 
115.52 (CH), 111.48 (CH), 76.84 (Cspiro), 62.60 (CH-4). Anal. Calc. for 
C28H20ClN3O.0.5H2O: C 74.29, H 4.53, N 9.29, Found: C 73.96, H 4.34, N 9.09. 
 
7-chloro-2',4',5'-triphenyl-2',4'-dihydrospiro[indoline-3,3'-
pyrazol]-2-one (2d) 
Following the general procedure, to a solution of 3d (0.075g, 
0.29mmol) in CH2Cl2 (2ml) was added 4a (0.075g, 0.32mmol, 1.1 
eq) and triethylamine (0.12 ml, 0.87 mmol, 3 eq). Reaction time: 10h. 
The compound was purified by flash chromatography (eluent: 
EtOAc/n-Hexane 1:3) and then recrystallized in diethyl ether to 
afford compound 2d as a white solid (0.1g, 0.3mmol, 90.9%). 
1H NMR (400 MHz, DMSO) δ 9.29 (d, J = 4.9 Hz, 2H, H), 9.22 (s, 1H, NH), 8.90 (s, 3H, 
H), 8.86 – 8.71 (m, 6H, H), 8.62 (s, 2H, H), 8.56 (d, J = 8.3 Hz, 2H, H), 8.50 (t, J = 7.3 Hz, 
1H, H), 8.21 (t, J = 7.9 Hz, 1H, H), 7.96 (d, J = 7.5 Hz, 1H, H), 6.82 (s, 1H, H-4). 
13C NMR (101 MHz, DMSO) δ 176.62 (C=O), 148.31 (C=N), 143.59 (Cq), 137.96 (Cq), 
133.87 (Cq), 130.96 (Cq), 128.85 (CH), 128.57 (CH), 128.41 (CH), 128.19 (CH), 128.15 
(CH), 127.81 (Cq), 127.52 (CH), 126.69 (CH), 126.26 (CH), 124.08 (CH), 122.21 (CH), 
120.61 (CH), 114.90 (CH), 114.79 (C-Cl), 77.07 (Cspiro), 62.22 (CH-4). Anal. Calc. for 
C28H20ClN3O: C 74.74, H 4.48, N 9.34, Found: C 74.4, H 4.69, N 8.86. 
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5-bromo-2',4',5'-triphenyl-2',4'-dihydrospiro[indoline-3,3'-
pyrazol]-2-one (2e) 
Following the general procedure, to a solution of 3e (0.075g, 
0.25mmol) in CH2Cl2 (2ml) was added 4a (0.07g, 0.28mmol, 1.1 
eq) and triethylamine (0.10 ml, 0.75 mmol, 3 eq). Reaction time: 
11h30min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:3) and then recrystallized in diethyl 
ether to afford compound 2e as a white solid (0.1g, 0.2mmol, 81.8%). 
IR (KBr): 3180 (NH), 1718 (C=O), 1618 (C=N) cm-1. 
1H NMR (400 MHz, DMSO.d6) δ 10.21 (s, 1H, NH), 7.86 – 7.69 (m, 2H, H), 7.41 (dd, J = 
22.4, 3.3 Hz, 3H, H, H), 7.34 – 7.25 (m, 4H, H), 7.23 (t, J = 7.2 Hz, 2H, H), 7.04 (d, J = 7.9 
Hz, 4H, H), 6.94 (t, J = 7.2 Hz, 1H, H), 6.82 (d, J = 8.2 Hz, 1H, H), 6.50 (s, 1H, H), 5.24 (s, 
1H, H-4). 
13C NMR (101 MHz, DMSO.d6) δ 176.86 (C=O), 148.13 (C=N), 143.56 (Cq), 139.42 
(Cq), 133.79 (Cq), 131.50 (CH), 130.96 (Cq), 128.78 (CH), 128.42 (CH), 128.16 (CH), 
127.74 (Cq), 127.13 (CH), 126.25 (CH), 120.46 (CH), 114.64 (CH), 113.99 (C-Br), 111.27 
(CH), 62.10 (CH-4). Anal. Calc. for C28H20BrN3O.0.55H2O: C 66.68, H 4.23, N 8.33, Found: 
C 66.29, H 4.09, N 8.18. 
 
6-bromo-2',4',5'-triphenyl-2',4'-dihydrospiro[indoline-3,3'-
pyrazol]-2-one (2f) 
Following the general procedure, to a solution of 3f (0.075g, 
0.25mmol) in CH2Cl2 (2ml) was added 4a (0.07g, 0.3mmol, 1.2 eq) 
and triethylamine (0.10 ml, 0.75 mmol, 3 eq). Reaction time: 5h. 
The compound was purified by flash chromatography (eluent: 
EtOAc/n-Hexane 1:3) and then recrystallized in dichloromethane to 
afford compound 2f as a white solid (0.07g, 0.14mmol, 83.9%). 
IR (KBr): 3172 (NH), 1720 (C=O), 1609 (C=N) cm-1. 
1H NMR (400 MHz, DMSO.d6) δ 9.90 (s, 1H, NH), 9.32 (d, J = 3.8 Hz, 2H, H), 8.95 – 
8.90 (m, 3H, H), 8.84 (s, 3H, H, H), 8.78 (t, J = 7.8 Hz, 2H, H), 8.67 – 8.55 (m, J = 14.9, 7.9 
Hz, 5H, H), 8.52 (t, J = 7.3 Hz, 1H, H), 8.39 (d, J = 8.1 Hz, 1H, H), 7.87 (d, J = 8.1 Hz, 1H, 
H), 6.78 (s, 1H, H-4). 
13C NMR (101 MHz, DMSO.d6) δ 177.12 (C=O), 148.45 (C=N), 143.72 (Cq), 141.90 
(Cq), 133.99 (Cq), 131.01 (Cq), 128.56 (CH), 128.29 (Cq), 127.81 (CH), 127.55 (CH), 126.97 
(CH), 126.26 (CH), 124.23 (CH), 124.06 (C-Br), 122.56 (CH), 120.60 (CH), 114.96 (CH), 
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113.33 (CH), 76.19 (Cspiro), 61.79 (CH-4). Anal. Calc. for C28H20BrN3O: C 68.02, H 4.048, 
N 8.50, Found: C 67.61, H 4.13, N 8.25. 
 
6-chloro-5-fluoro-2',4',5'-triphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2g) 
Following the general procedure, to a solution of 3g (0.0175g, 
0.06mmol) in CH2Cl2 (2ml) was added 4a (0.04g, 0.16mmol, 2.5 
eq) and triethylamine (0.023 ml, 0.15 mmol, 2.5 eq). Reaction time: 
46h30min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:3) to afford compound 2g as a white 
solid (0.01g, 0.03mmol, 40.0%). 
IR (KBr): 3419 (NH), 1730 (C=O), 1597 (C=N) cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.94 (s, 1H, NH), 7.63 (d, J = 3.6 Hz, 2H, H), 7.28 – 7.21 
(m, 3H, H), 7.17 (s, 3H, H), 7.13 – 7.01 (m, 2H, H), 6.99 – 6.79 (m, 5H, H), 6.76 (d, J = 5.8 
Hz, 1H, H), 6.08 (d, J = 8.4 Hz, 1H, H), 5.08 (s, 1H, H-4). 
13C NMR (75 MHz, CDCl3) δ 178.47 (C=O), 149.23 (C=N), 144.07 (Cq), 136.44 (d, J = 
2.7 Hz, C-F), 133.97 (Cq), 131.37 (Cq), 129.16 (CH), 128.66 (CH), 126.99 (CH), 125.80 (d, J 
= 7.2 Hz, C-Cl), 122.22 (Cq), 121.96 (Cq), 121.69 (CH), 115.48 (CH), 115.34 (CH), 115.00 
(CH), 112.52 (CH), 77.00 (Cspiro), 62.81 (CH-4). Anal. Mass for C28H19ClFN3O: 467.1, 
Found: 468.3. 
 
7-chloro-2'-(2-chlorophenyl)-4',5'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2h) 
Following the general procedure, to a solution of 3d (0.05g, 
0.20mmol) in CH2Cl2 (1.5ml) was added 4b (0.08g, 0.29mmol, 1.5 
eq) and N,N-Diisopropylethylamine (0.10 mL, 0.59 mmol, 3 eq.). 
Reaction time: 23h. The compound was purified by flash 
chromatography (eluent: EtOAc/n-Hexane 1:4) to afford compound 
2h as a white solid (0.09g, 0.18mmol, 93.9%). 
IR (KBr): 3412 (NH), 1720 (C=O), 1620 (C=N) cm-1. 
1H NMR (300 MHz, CDCl3) δ 7.79 (s, 1H, NH), 7.71 – 7.63 (m, 2H, H), 7.44 (dd, J = 8.4, 
1.3 Hz, 1H, H), 7.28 (d, J = 3.3 Hz, 2H, H), 7.23 – 7.13 (m, 6H, H), 7.09 – 7.01 (m, 3H, H), 
6.98 (dd, J = 7.2, 2.3 Hz, 2H, H), 6.34 (t, J = 7.9 Hz, 1H, H), 5.89 (d, J = 7.5 Hz, 1H, H), 5.07 
(s, 1H, H-4). 
13C NMR (75 MHz, CDCl3) δ 177.61 (C=O), 151.84 (C=N), 141.18 (Cq), 138.50 (Cq), 
134.80 (Cq), 131.51 (Cq), 130.37 (CH), 129.72 (CH), 129.22 (CH), 129.11 (CH), 128.95 
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(CH), 128.55 (CH), 128.24 (CH), 127.27 (CH), 127.12 (Cq), 126.55 (CH), 126.00 (CH), 
125.88 (Cq), 125.50 (CH), 122.42 (CH), 114.65 (C-Cl), 78.98 (Cspiro), 62.59 (CH-4). Anal. 
Calc. for C28H19Cl2N3O: C 69.42, H 3.96, N 8.68, Found: C 69.04, H 3.78, N 9.30. 
 
5'-(4-methoxyphenyl)-2',4'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2i) 
Following the general procedure, to a solution of 3a (0.075g, 
0.34mmol) in CH2Cl2 (2ml) was added 4c (0.13g, 0.51mmol, 1.5 eq) 
and triethylamine (0.14 ml, 1.02 mmol, 3 eq). Reaction time: 17h. 
The compound was purified by flash chromatography (eluent: 
EtOAc/n-Hexane 1:3) to afford compound 2i as a white solid (0.1g, 
0.3mmol, 73.5%). 
IR (KBr): 3362 (NH), 1741 (C=O), 1600 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 8.63 (s, 1H, NH), 7.62 (d, J = 8.8 Hz, 2H, H), 7.16 – 7.00 
(m, 6H, H), 6.94 (t, J = 8.3 Hz, 4H, H), 6.80 (t, J = 9.0 Hz, 3H, H, H), 6.74 (d, J = 7.8 Hz, 1H, 
H), 6.57 (t, J = 7.5 Hz, 1H, H), 6.36 (d, J = 7.4 Hz, 1H, H), 5.13 (s, 1H, H-4), 3.78 (s, 3H, 
CH3). 
13C NMR (101 MHz, CDCl3) δ 178.52 (C=O), 160.08 (C=N), 148.81 (C-O), 144.48 (Cq), 
139.89 (Cq), 134.75 (Cq), 129.31 (CH), 129.21 (CH), 128.91 (CH), 128.53 (CH), 128.36 
(CH), 127.88 (CH), 126.47 (CH), 125.72 (Cq), 124.41 (Cq), 122.36 (CH), 120.78 (CH), 
115.25 (CH), 113.86 (CH), 110.44 (CH), 77.23 (Cspiro), 62.78 (CH-4), 55.26 (O-CH3). Anal. 
Calc. for C29H23N3O2: C 78.18, H 5.20, N 9.43, Found: C 77.96, H 5.19, N 9.34. 
 
5-chloro-5'-(4-methoxyphenyl)-2',4'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2j) 
Following the general procedure, to a solution of 3b (0.075g, 
0.29mmol) in CH2Cl2 (2ml) was added 4c (0.12g, 0.44mmol, 1.5 
eq) and triethylamine (0.12 ml, 0.87 mmol, 3 eq). Reaction time: 
18h30min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:3) and then recrystallized in diethyl 
ether to afford compound 2j as a white solid (0.05g, 0.1mmol, 
33.4%). 
IR (KBr): 1740 (NH), 1711 (C=O), 1599 (C=N) cm-1. 
1H NMR (400 MHz, DMSO.d6) δ 10.97 (s, 1H, NH), 7.61 (d, J = 8.5 Hz, 2H, H), 7.27 – 
7.15 (m, 4H, H), 7.12 (t, J = 7.7 Hz, 2H, H), 7.00 (d, J = 6.7 Hz, 2H, H), 6.92 (d, J = 8.5 Hz, 
2H, H), 6.87 (d, J = 8.3 Hz, 1H, H), 6.78 (dd, J = 12.6, 7.8 Hz, 3H, H, H), 6.12 (s, 1H, H), 
5.41 (s, 1H, H-4), 3.74 (s, 3H, CH3). 
O
N
H
N
N
O
Cl
4´ 
N
H
N
N
O
O
4´ 
74 
 
13C NMR (101 MHz, DMSO.d6) δ 176.36 (C=O), 159.90 (C=N), 149.44 (C-O), 144.20 
(Cq), 140.31 (Cq), 134.71 (Cq), 129.30 (CH), 128.95 (CH), 128.50 (CH), 128.16 (CH), 
127.88 (CH), 127.26 (C-Cl), 125.52 (Cq), 125.45 (CH), 123.65 (Cq), 120.30 (CH), 114.23 
(CH), 114.08 (CH), 111.58 (CH), 75.66 (Cspiro), 61.02 (CH-4), 55.20 (O-CH3). Anal. Calc. 
for C29H22ClN3O2.1.25H2O: C 69.43, H 4.93, N 8.38, Found: C 69.42, H 4.92, N 8.56. 
 
7-chloro-5'-(4-methoxyphenyl)-2',4'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2k) 
Following the general procedure, to a solution of 3d (0.075g, 
0.29mmol) in CH2Cl2 (2ml) was added 4c (0.08g, 0.32mmol, 1.1 eq) 
and triethylamine (0.12 ml, 0.87 mmol, 3 eq). Reaction time: 24 
hours. The compound was purified by flash chromatography (eluent: 
EtOAc/n-Hexane 1:4) and then recrystallized in diethyl ether to 
afford compound 2k as a white solid (0.10g, 0.2mmol, 71.1%). 
IR (KBr): 3204 (NH), 1732 (C=O), 1608 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 7.78 (s, 1H, NH), 7.59 (d, J = 8.8 Hz, 2H, H), 7.16 (dd, J = 
7.6, 4.5 Hz, 3H, H), 7.13 – 7.05 (m, 3H, H), 6.98 (s, 2H, H), 6.91 (d, J = 7.9 Hz, 2H, H), 6.85 
(d, J = 7.3 Hz, 1H, H), 6.80 (d, J = 8.9 Hz, 2H, H), 6.55 (t, J = 7.9 Hz, 1H, H), 6.30 (d, J = 7.5 
Hz, 1H, H), 5.14 (s, 1H, H-4), 3.77 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 176.78 (C=O), 160.30 (C=N), 149.06 (C-O), 144.49 (Cq), 
137.57 (Cq), 134.51 (Cq), 129.35 (CH), 129.29 (CH), 129.13 (CH), 128.80 (CH), 128.51 
(CH), 128.24 (CH), 127.51 (Cq), 124.99 (CH), 124.23 (Cq), 123.30 (CH), 121.39 (CH), 
115.70 (CH), 115.22 (C-Cl), 114.00 (CH), 77.90 (Cspiro), 63.22 (CH-4), 55.39 (O-CH3). 
Anal. Calcd for C29H22ClN3O2: C 72.57, H 4.63, N 8.76, Found: C 72.34, H 4.56, N 8.66. 
 
 6-bromo-5'-(4-methoxyphenyl)-2',4'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2l) 
Following the general procedure, to a solution of 3f (0.075g, 
0.25mmol) in CH2Cl2 (2ml) was added 4c (0.08g, 0.3mmol, 1.2 eq) 
and triethylamine (0.10 ml, 0.75 mmol, 3 eq). Reaction time: 
3h10min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:3) and then recrystallized in diethyl 
ether to afford compound 2l as a white solid (0.12g, 0.28mmol, 
91.6%). 
IR (KBr): 3220 (NH), 1747 (C=O), 1608 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 8.76 (s, 1H, NH), 7.61 (d, J = 8.5 Hz, 2H, H), 7.17 (d, J = 
3.0 Hz, 3H, H), 7.11 (t, J = 7.8 Hz, 2H, H), 6.96 (s, 2H, H, H), 6.91 (d, J = 9.4 Hz, 3H, H), 
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6.83 (dd, J = 11.7, 8.2 Hz, 3H, H), 6.71 (d, J = 8.1 Hz, 1H, H), 6.17 (d, J = 8.1 Hz, 1H, H), 
5.07 (s, 1H, H-4), 3.78 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 178.46 (C=O), 160.33 (C=N), 149.20 (C-O), 144.54 (Cq), 
141.24 (Cq), 134.54 (Cq), 129.23 (CH), 129.15 (CH), 128.92 (CH), 128.52 (CH), 128.32 
(CH), 127.74 (CH), 125.54 (CH), 124.86 (Cq), 124.25 (C-Br), 123.28 (Cq), 121.31 (CH), 
115.51 (CH), 114.12 (CH), 114.04 (CH), 77.26 (Cspiro), 62.75 (CH-4), 55.41 (O-CH3). Anal. 
Calcd for C29H22BrN3O2.0.2H2O: C 65.96, H 4.28, N 7.96, Found: C 65.60, H 4.39, N 7.70. 
 
6-chloro-4'-(3-chlorophenyl)-5'-(4-methoxyphenyl)-2'-
phenyl-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-2-one (2m) 
Following the general procedure, to a solution of 3h (0.075g, 
0.26mmol) in CH2Cl2 (2ml) was added 4c (0.14g, 0.52mmol, 2 eq) 
and triethylamine (0.11 ml, 0.78 mmol, 3 eq). Reaction time: 22 
hours. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:3) and then recrystallized in diethyl 
ether to afford compound 2m as a white solid (0.13g, 0.25mmol, 
97.8%). 
IR (KBr): 3406 (NH), 1703 (C=O), 1597 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H, NH), 7.59 (d, J = 8.8 Hz, 2H, H), 7.17 (d, J = 
8.3 Hz, 1H, H), 7.11 (t, J = 7.8 Hz, 3H, H), 6.97 (s, 1H, H), 6.90 (d, J = 7.9 Hz, 2H, H), 6.84 
(t, J = 8.3 Hz, 4H, H), 6.78 (d, J = 1.5 Hz, 1H, H), 6.62 (dd, J = 8.1, 1.7 Hz, 1H, H), 6.28 (d, J 
= 8.1 Hz, 1H, H), 5.02 (s, 1H, H-4), 3.79 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 178.29 (C=O), 160.49 (C=N), 148.59 (C-O), 144.34 (Cq), 
141.13 (Cq), 136.73 (C-Cl), 135.65 (Cq), 134.87 (C-Cl), 130.18 (CH), 129.18 (CH), 128.58 
(CH), 128.46 (CH), 127.48 (CH), 127.29 (Cq), 123.88 (Cq), 122.77 (CH), 121.51 (CH), 
115.59 (CH), 114.17 (CH), 111.62 (CH), 76.66 (Cspiro), 62.20 (CH-4), 55.43 (O-CH3). Anal. 
Calcd for C29H21Cl2N3O2: C 67.71, H 4.11, N 8.17, Found: C 67.19, H 4.15, N 7.98. 
 
5'-(tert-butyl)-2',4'-diphenyl-2',4'-dihydrospiro[indoline-3,3'-
pyrazol]-2-one (2n) 
Following the general procedure, to a solution of 3a (0.05g, 
0.26mmol) in CH2Cl2 (2ml) was added 4d (0.1g, 0.47mmol, 2 eq) 
and triethylamine (0.11 ml, 0.78 mmol, 3 eq). Reaction time: 
5h30min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:3) and then recrystallized in dichloromethane:n-hexane to afford 
compound 2n as a white solid (0.07g, 0.16mmol, 72.7%). 
IR (KBr): 3236 (NH), 1709 (C=O), 1599 (C=N) cm-1. 
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1H NMR (300 MHz, CDCl3) δ 7.65 (s, 1H, NH), 7.35 (s, 2H, H), 7.12 (dd, J = 7.7, 1.2 Hz, 
2H, H), 7.09 – 6.99 (m, 3H, H), 6.83 (dd, J = 8.8, 1.0 Hz, 3H, H), 6.80 – 6.74 (m, 2H, H), 
6.57 (td, J = 7.6, 1.0 Hz, 1H, H), 6.24 (d, J = 7.2 Hz, 1H, H), 4.46 (s, 1H, H-4), 1.19 (s, 9H, 
CH3). 
13C NMR (75 MHz, CDCl3) δ 178.37 (C=O), 161.70 (C=N), 145.79 (Cq), 140.40 (Cq), 
135.29 (Cq), 129.28 (CH), 128.90 (CH), 128.12 (CH), 126.41 (CH), 125.74 (Cq), 122.24 
(CH), 120.92 (CH), 115.96 (CH), 110.46 (CH), 77.28 (Cspiro), 62.32 (CH-4), 34.87 
(C(CH3)3), 29.49 (C(CH3)3). Anal. Calc. for C26H25N3O.0.05H2O: C 78.77, H 6.40, N 10.60, 
Found: C 77.70, H 6.47, N 10.18. 
 
5'-(tert-butyl)-5-chloro-2',4'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2o) 
Following the general procedure, to a solution of 3b (0.05g, 
0.27mmol) in CH2Cl2 (2ml) was added 4d (0.09g, 0.47mmol, 2 eq) 
and triethylamine (0.09 ml, 0.68 mmol, 3 eq). Reaction time: 
4h50min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:2) to afford compound 2o as a white solid (0.08g, 0.19mmol, 
80.2%). 
IR (KBr): 3254 (NH), 1718 (C=O), 1691 (C=N) cm-1. 
1H NMR (300 MHz, CDCl3) δ 7.62 (s, 1H, NH), 7.47 – 7.39 (m, 1H, H), 7.31 (d, J = 7.8 
Hz, 1H, H), 7.20 (dd, J = 10.8, 8.7 Hz, 1H, H), 7.12 – 7.03 (m, 1H, H), 6.84 (s, 2H, H, H), 
6.82 – 6.78 (m, 2H, H), 6.69 (d, J = 8.3 Hz, 1H, H), 6.15 (d, J = 2.1 Hz, 1H, H), 4.46 (s, 1H, 
H-4), 1.19 (s, 9H, CH3). 
13C NMR (75 MHz, CDCl3) δ 177.60 (C=O), 161.51 (C=N), 145.42 (Cq), 138.52 (Cq), 
134.53 (Cq), 129.18 (CH), 129.09 (CH), 128.87 (CH), 128.39 (Cq), 127.71 (C-Cl), 127.46 
(CH), 126.64 (CH), 121.13 (CH), 115.87 (CH), 113.52 (CH), 111.06 (CH), 77.16 (Cspiro), 
62.39 (CH-4), 34.74 (C(CH3)3), 29.33 (C(CH3)3). Anal. Calc. for C26H24ClN3O.0.05AcOEt: C 
72.45, H 5.67, N 9.68, Found: C 72.47, H 5.74, N 9.52. 
 
5'-(tert-butyl)-6-chloro-2',4'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2p) 
Following the general procedure, to a solution of 3c (0.075g, 
0.29mmol) in CH2Cl2 (2ml) was added 4d (0.13g, 0.59mmol, 2 eq) 
and triethylamine (0.12 ml, 0.87 mmol, 3 eq). Reaction time: 
15h30min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:3) to afford compound 2p as a white solid (0.1g, 0.23mmol, 
79.1%). 
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IR (KBr): 3213 (NH), 1724 (C=O), 1608 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H, NH), 7.35 (s, 2H, H), 7.26 (q, J = 6.9 Hz, 1H, 
H), 7.15 (s, 1H, H), 7.06 (t, J = 7.9 Hz, 2H, H), 6.81 (t, J = 8.3 Hz, 3H, H), 6.74 (d, J = 1.5 
Hz, 1H, H), 6.66 (s, 1H, H), 6.55 (dd, J = 8.2, 1.7 Hz, 1H, H), 6.12 (d, J = 8.2 Hz, 1H, H), 
4.43 (s, 1H, H-4, H), 1.19 (s, 9H, CH3). 
13C NMR (101 MHz, CDCl3) δ 177.91 (C=O), 161.88 (C=N), 145.72 (Cq), 141.38 (Cq), 
135.18 (Cq), 134.99 (C-Cl), 128.99 (CH), 128.37 (CH), 127.39 (CH), 124.32 (Cq), 122.43 
(CH), 121.41 (CH), 116.29 (CH), 111.05 (CH), 77.05 (Cspiro), 62.36 (CH-4), 34.91 
(C(CH3)3), 29.49 (C(CH3)3). Anal. Calc. for C26H24ClN3O.0.5CH2Cl2: C 67.37, H 5.34, N 
8.90, Found: C 67.14, H 5.39, N 8.84. 
 
5'-(tert-butyl)-7-chloro-2',4'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2q) 
Following the general procedure, to a solution of 3d (0.075g, 
0.29mmol) in CH2Cl2 (2ml) was added 4d (0.075g, 0.35mmol, 1.2 
eq) and triethylamine (0.12 ml, 0.87 mmol, 3 eq). Reaction time: 3 
hours. The compound was purified by flash chromatography (eluent: 
EtOAc/n-Hexane 1:3) and then recrystallized in diethyl ether to afford compound 2q as a 
white solid (0.11g, 0.26mmol, 87.2%). 
IR (KBr): 3177 (NH), 1752 (C=O), 1712 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 7.89 (s, 1H, NH), 7.36 (s, 2H, H), 7.27 – 7.23 (m, 1H, H), 
7.09 (dd, J = 15.8, 8.1 Hz, 4H, H), 6.88 – 6.78 (m, 3H, CH, H), 6.68 (s, 1H, H), 6.53 (t, J = 
7.9 Hz, 1H, H), 6.15 (d, J = 7.6 Hz, 1H, H), 4.49 (s, 1H, H-4), 1.19 (s, 9H, CH3). 
13C NMR (101 MHz, CDCl3) δ 176.50 (C=O), 161.89 (C=N), 145.63 (Cq), 137.96 (Cq), 
134.94 (Cq), 129.24 (CH), 129.01 (CH), 128.34 (CH), 127.46 (Cq), 124.85 (CH), 123.06 
(CH), 121.55 (CH), 116.54 (CH), 115.12 (C-Cl), 78.17 (Cspiro), 62.59 (CH-4), 34.90 
(C(CH3)3), 29.48 (C(CH3)3). Anal. Calcd for C26H24ClN3O.0.4H2O: C 71.43, H 5.73, N 9.61, 
Found: C 71.11, H 5.70, N 9.30. 
 
5-bromo-5'-(tert-butyl)-2',4'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2r) 
Following the general procedure, to a solution of 3e (0.05g, 
0.18mmol) in CH2Cl2 (2ml) was added 4d (0.09g, 0.43mmol, 2.5 
eq) and triethylamine (0.06 ml, 0.43 mmol, 2.5 eq). Reaction time: 
5h30min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:1) to afford compound 2r as a white solid (0.03, 0.06mmol, 
41.5%). 
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IR (KBr): 3254 (NH), 1726 (C=O), 1695 (C=N) cm-1. 
1H NMR (300 MHz, CDCl3) δ 7.69 (s, 1H, NH), 7.42 (s, 1H, H), 7.31 (t, J = 7.2 Hz, 2H, 
H), 7.24 (d, J = 2.0 Hz, 1H, H), 7.22 (d, J = 2.0 Hz, 1H, H), 7.07 (dd, J = 8.6, 7.4 Hz, 2H, H), 
6.86 – 6.80 (m, 3H, H), 6.64 (d, J = 8.3 Hz, 2H, H), 6.27 (d, J = 1.9 Hz, 1H, H), 4.45 (s, 1H, 
H-4), 1.19 (s, 9H, CH3). 
13C NMR (75 MHz, CDCl3) δ 177.17 (C=O), 161.68 (C=N), 145.62 (Cq), 139.06 (Cq), 
134.71 (Cq), 132.11 (CH), 132.11 (CH), 129.73 (CH), 129.73 (CH), 129.04 (CH), 129.04 
(CH), 128.59 (CH), 127.97 (Cq), 121.42 (CH), 116.21 (CH), 115.20 (C-Br), 111.45 (CH), 
77.36 (Cspiro), 62.63 (CH-4), 34.91 (C(CH3)3), 29.50 (C(CH3)3). Anal. Mass for 
C26H24BrN3O: 475.1, Found: 476.3. 
 
 6-bromo-5'-(tert-butyl)-2',4'-diphenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2s) 
Following the general procedure, to a solution of 3f (0.075g, 
0.25mmol) in CH2Cl2 (2ml) was added 4d (0.06g, 0.3mmol, 1.2 eq) 
and triethylamine (0.10 ml, 0.75 mmol, 3 eq). Reaction time: 
1h30min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:3) and then recrystallized in diethyl ether to afford compound 2s 
as a white solid (0.11, 0.23mmol, 92.1%). 
IR (KBr): 3218 (NH), 1723 (C=O), 1610 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 8.48 (s, 1H, NH), 7.34 (s, 2H, H), 7.26 (q, J = 7.1 Hz, 1H, 
H), 7.15 (s, 1H, H), 7.07 (t, J = 7.9 Hz, 2H, H), 6.90 (s, 1H, H), 6.81 (t, J = 7.5 Hz, 3H, H), 
6.73 – 6.58 (m, 2H, H, H), 6.05 (d, J = 8.1 Hz, 1H, H), 4.43 (s, 1H, H-4), 1.18 (s, 9H, CH3). 
13C NMR (101 MHz, CDCl3) δ 177.88 (C=O), 161.89 (C=N), 145.70 (Cq), 141.50 (Cq), 
134.93 (Cq), 129.01 (CH), 128.38 (CH), 127.65 (Cq), 125.35 (CH), 124.86 (CH), 123.15 (C-
Br), 121.39 (CH), 116.21 (CH), 113.87 (CH), 77.09 (Cspiro), 62.29 (CH-4), 34.90 (C(CH3)3), 
29.49 (C(CH3)3). Anal. Calcd for C26H24BrN3O.0.05H2O: C 65.70, H 5.12, N 8.84, Found: C 
65.32, H 5.02, N 8.64. 
 
 5'-(tert-butyl)-6-chloro-4'-(3-chlorophenyl)-2'-phenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2t) 
Following the general procedure, to a solution of 3h (0.075g, 
0.26mmol) in CH2Cl2 (2ml) was added 4d (0.11g, 0.52mmol, 2 eq) 
and triethylamine (0.11 ml, 0.78 mmol, 3 eq). Reaction time: 
18h30min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:3) and then recrystallized in diethyl ether to afford compound 2t 
as a white solid (0.10, 0.23mmol, 82.7%). 
N
H
O
N
N
Br
4´ 
N
H
N
N
O
Cl
Cl
4´ 
79 
 
IR (KBr): 3419 (NH), 1720 (C=O), 1616 (C=N) cm-1. 
1H NMR (400 MHz, CDCl3) δ 8.40 (s, 1H, NH), 7.31 (s, 1H, H), 7.28 – 7.20 (m, 2H, H), 
7.07 (t, J = 7.8 Hz, 2H, H), 6.83 (t, J = 7.1 Hz, 3H, H), 6.76 (s, 1H, H), 6.73 – 6.50 (m, 2H, 
H), 6.18 (s, 1H, H), 4.40 (s, 1H, H-4), 1.19 (s, 9H, CH3). 
13C NMR (101 MHz, CDCl3) δ 177.60 (C=O), 161.34 (C=N), 145.48 (Cq), 141.42 (Cq), 
137.17 (Cq), 135.52 (C-Cl), 134.81 (C-Cl), 129.72 (CH), 129.04 (CH), 128.62 (CH), 127.27 
(CH), 123.88 (Cq), 122.62 (CH), 121.67 (CH), 116.41 (CH), 111.30 (CH), 76.97 (Cspiro), 
61.75 (CH-4), 34.96 (C(CH3)3), 29.47 (C(CH3)3). Anal. Calcd for C26H23Cl2N3O.0.6CH2Cl2: 
C 67.25, H 4.99, N 9.05, Found: C 66.61, H 5.14, N 8.82. 
 
5'-(tert-butyl)-2'-(2-chlorophenyl)-4'-phenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2u) 
Following the general procedure, to a solution of 3a (0.05g, 
0.26mmol) in CH2Cl2 (2ml) was added 4e (0.08g, 0.33mmol, 1.5 eq) 
and triethylamine (0.115 mL, 0.083 mmol, 3 eq.). Reaction time: 
26h50min. The compound was purified by flash chromatography 
(eluent: EtOAc/n-Hexane 1:4) to afford compound 2u as a white solid (0.06, 0.14mmol, 
61.8%). 
IR (KBr): 3419 (NH), 1716 (C=O), 1618 (C=N) cm-1. 
1H NMR (300 MHz, CDCl3) δ 7.91 (s, 1H, NH), 7.31 – 7.26 (m, 2H, H), 7.22 (d, J = 6.3 
Hz, 1H, H), 7.14 (d, J = 9.2 Hz, 2H, H), 7.08 (d, 1H, H), 6.99 (t, J = 7.8 Hz, 1H, H), 6.93 (t, J 
= 7.8 Hz, 1H, H), 6.67 (d, J = 7.8 Hz, 1H, H), 6.38 (t, J = 7.8 Hz, 1H, H), 5.89 (d, J = 7.6 Hz, 
1H, H), 4.40 (s, 1H, H-4), 1.20 (s, 9H,CH3).  
13C NMR (75 MHz, CDCl3) δ 178.55 (C=O), 164.14 (C=N), 141.65 (Cq), 140.88 (Cq), 
135.54 (Cq), 130.27 (CH), 129.85 (C-Cl), 129.17 (CH), 128.62 (CH), 128.06 (CH), 127.60 
(CH), 127.03 (CH), 125.72 (CH), 124.79 (CH), 123.70 (Cq), 121.52 (CH), 109.49 (CH), 
77.95 (Cspiro), 61.79 (CH-4), 34.93 (C(CH3)3), 29.51 (C(CH3)3). Anal. Mass for 
C26H23ClN3O: 429.2, Found: 430.3. 
 
5'-(tert-butyl)-5-chloro-2'-(2-chlorophenyl)-4'-phenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2v) 
Following the general procedure, to a solution of 3b (0.05g, 
0.02mmol) in CH2Cl2 (2ml) was added 4e (0.12g, 0.41mmol, 3 eq) 
and N,N-Diisopropylethylamine (0.118 mL, 0.068 mmol, 3 eq.). 
Reaction time: 21 hours. The compound was purified by flash 
chromatography (eluent: EtOAc/n-Hexane 1:4) to afford compound 2v as a white solid (0.03, 
0.05mmol, 27.5%). 
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IR (KBr): 3383 (NH), 1722 (C=O), 1620 (C=N) cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.56 (s, 1H, NH), 7.57 – 7.38 (m, 2H, H, H), 7.33 – 7.22 
(m, 3H, H), 7.20 – 7.06 (m, 3H, H), 6.95 (d, J = 5.5 Hz, 2H, H), 6.61 (d, J = 7.1 Hz, 1H, H), 
5.78 (s, 1H, H), 4.39 (s, 1H, H-4), 1.20 (s, 9H, CH3). 
13C NMR (75 MHz, CDCl3) δ 178.34 (C=O), 164.16 (C=N), 141.42 (Cq), 139.48 (Cq), 
134.91 (Cq), 130.39 (CH), 129.81 (C-Cl), 129.10 (CH), 128.42 (CH), 127.91 (CH), 127.16 
(C-Cl), 126.93 (CH), 126.11 (CH), 125.45 (Cq), 124.95 (CH), 110.47 (CH), 78.18 (Cspiro), 
61.93 (CH-4), 34.94 (C(CH3)3), 29.48 (C(CH3)3). Anal. Mass for C26H23Cl2N3O: 463.1, 
Found: 464.3. 
 
5'-(tert-butyl)-7-chloro-2'-(2-chlorophenyl)-4'-phenyl-2',4'-
dihydrospiro[indoline-3,3'-pyrazol]-2-one (2x) 
Following the general procedure, to a solution of 3d (0.07g, 
0.27mmol) in CH2Cl2 (2ml) was added 4e (0.11g, 0.45mmol, 1.5 eq) 
and N,N-Diisopropylethylamine (0.13 mL, 0.82 mmol, 3 eq.). 
Reaction time: 22h20min. The compound was purified by flash 
chromatography (eluent: EtOAc/n-Hexane 1:4) to afford compound 2x as a white solid (0.09, 
0.2mmol, 70.8%). 
IR (KBr): 3407 (NH), 1712 (C=O), 1620 (C=N) cm-1. 
1H NMR (300 MHz, CDCl3) δ 7.51 (s, 1H, NH), 7.35 (dd, J = 8.6, 1.6 Hz, 1H, H), 7.26 (m, 
3H, H), 7.20 – 7.10 (m, 3H, H), 7.01 – 6.93 (m, 2H, H), 6.68 (s, 1H, H), 6.40 – 6.29 (m, 1H, 
H), 5.83 (d, J = 7.6 Hz, 1H, H), 4.42 (s, 1H, H-4), 1.19 (s, 9H, CH3). 
13C NMR (75 MHz, CDCl3) δ 177.63 (C=O), 164.32 (C=N), 141.50 (Cq), 138.70 (Cq), 
135.14 (Cq), 130.16 (C-Cl), 129.14 (CH), 128.24 (CH), 127.19 (CH), 126.22 (CH), 125.94 
(CH), 125.53 (CH), 125.18 (Cq), 122.22 (CH), 114.54 (C-Cl), 78.97 (Cspiro), 61.97 (CH-4), 
34.92 (C(CH3)3), 29.46 (C(CH3)3). Anal. Calc. for C26H23Cl2N3O.0.05H2O: C 67.24, H 5.00, 
N 9.05, Found: C 69.62, H 5.12, N 9.19. 
 
6.2. STABILITY 
6.2.1. HPLC Analysis 
High-performance liquid chromatography (HPLC) measurements were carried out using a 
VWR HITACHI assembly equipped with a UV detector L-2400, a column oven L-2300, and 
a pump L-2130. An injection valve equipped with 20μL sample loop was used. The 
separation was performed on a LichroCART® RP-18 (5μm, 250-4 mm) analytical column 
(Merck). Acetonitrile: H2O (95:5, v:v) was used as eluent system for compounds. Elution was 
performed at a solvent flow rate of 1 mL/min. Chromatograms were monitored by UV 
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detection at 263 nm. All analyses were performed at 35 ºC. Acquisition and treatment of data 
were done using Ezchrom Elite software. 
 
6.2.2. Stability in pH 7.4 Phosphate Buffer 
For this part of the project, 250μL of a 10-3M stock solution of tested compounds in 
DMSO were added to 2.5mL of potassium phosphate buffer solution (pH 7.4, 0.5M) at 37ºC. 
At appropriate intervals, samples (100μL) and analyzed by HPLC using the methodology 
previously described. The stability was assessed for a period of 72 hours.  
 
6.3. BIOLOGY 
6.3.1. Cell lines: tissue types, handling and maintenance  
The cell lines used in this work are summarized in Table 8. Further, primary cultures of 
mouse mixed glial cells were also used.  
Table 6 - Cell line general characterization. 
Cell Line 
Designation Disease Organism Morphology 
Culture 
properties 
Growth media 
% in (v/v) 
HCT-116 +/+ Colorectal carcinoma Human Epithelial Adherent 
McCoy´s; 
10 % FBS; 
1% Pen/Strep 
HCT-116 -/- Colorectal carcinoma Human Epithelial Adherent 
McCoy´s; 
10% FBS; 
1% Pen/Strep 
GL-261 Glioma Mouse - Adherent 
DMEM; 
10% FBS; 
1% Pen/Strep 
MCF-7 Brest adenocarcinoma Human Epithelial Adherent 
RPMI 1640; 
10% FBS; 
1% Pen/Strep 
2mM L-glutamine 
MDA-MB-231 Brest adenocarcinoma Human Epithelial Adherent 
RPMI 1640; 
10% FBS; 
1% Pen/Strep 
2mM L-glutamine 
Hek-293T Normal Human Epithelial Adherent 
RPMI 1640; 
10% FBS; 
1% Pen/Strep 
2mM L-glutamine 
CCD-18Co Normal Human Fibroblast Adherent 
DMEM; 
10% FBS 
1% Pen/Strep 
1% Glutamax; 
1% NEAA; 
0.025% TNF-α Human 
 
All cell lines were cultivated and maintained in 75 cm2 BD vented cell culture flasks (BD 
Biosciences, New Jersey, EUA) in a CO2 incubator at 37⁰C and humidified atmosphere of 5% 
CO2. 
Culture cell renewal was performed when cells reached approximately 80% confluence, 
which represents the critical point when cells start to detach and degenerate due to lack of 
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nutrients and contact inhibition. Briefly, cells were detached by adding TrypLE reagent 
(Gibco, Thermo Fisher Scientific, Waltham, USA) and incubate for 5 min in the CO2 
incubator. After that, cell suspension was transferred into 15 mL tubes and centrifuged at 500 
g for 5 min at room temperature. Cell pellet was then resuspended in fresh medium and 
subsequently incubated at 37⁰C and 5% (v/v) CO2 for further usage. 
Primary mouse mixed glial cultures were performed and kindly provided by Pedro 
Dionísio from Prof. Cecília Rodrigues’ group within iMed.ULisboa. Briefly, the cerebral 
hemispheres of 2-day-old mice were isolated and the meninges and blood vessels were 
removed, as described previously95. Cells were collected by passing the tissue, in DMEM F12 
containing antibiotics and fungicide, through a series of nylon screens with decreasing pore 
sizes. Cells were then centrifuged (300 g, 10 min) and resuspended in DMEM F12 containing 
10% FBS. The cell suspension was distributed into 96-well plates and incubated at 37°C in a 
humidified atmosphere of 5% CO2. Medium was replaced every 3 days. Confluent cultures 
(21 days) were used for compound testing. 
 
6.3.2. Evaluation of cell death and viability 
HCT-116 and GL-261 cells were plated in 96-well plates at 5x103 cells/well, while 
CCD18-co colon fibroblasts and primary mouse mixed glial cells at 4x103 cells/well. Hek-
293T, MCF-7 and MDA-MB-231 cells were cultured and maintained by Prof. Lídia 
Gonçalves from iMed.ULisboa. These cells were plated in 96-well plates at 1x104 cells/well. 
Viable cells were counted by the Trypan blue exclusion method in a hemocytometer from a 
mixture of 9:1 of Trypan blue at 0.4% (v/v) (Sigma, St. Louis, United States of America) and 
cellular suspension, using equation (1)  
 
(1) 
 
Compounds were dissolved in DMSO and diluted in culture medium to appropriate in 
range concentrations of μM.  
Twenty-four hours after cell plating, media was removed and replaced with fresh medium 
containing each compound in the appropriate concentration for additional 48 h/72 h (Scheme 
5). The same amount of DMSO was added to control cells. Cell viability and cell death were 
analyzed by standard methods as detailed below. 
 
 
 
Assay for 
viable cells Cell seeding Drug Addition 
Record 
Data 
24 hours 48/72 hours 30min. - 3h15min. 
Plating Exposure MTS/MTT 
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Cell viability was evaluated using the CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (Promega, Madison, USA), according to the manufacturer’s instructions. 
This homogenous, colorimetric method determines the number of viable cells in cytotoxicity 
assays. The assay is composed of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) and an electron coupling reagent phenazine 
methosulfate (PMS). MTS is bioreduced by cells into a formazan product that can be 
measured spectrophotometrically at 490 nm in a plate reader. The conversion of MTS into the 
formazan product is accomplished by dehydrogenase enzymes found in metabolically active 
cells, and is directly proportional to the number of viable cells in culture96. In brief, cell 
culture supernatants were replaced by 100 µL of MTS/PMS (19:1) solution prepared in fresh 
RPMI/ITSF, and cells incubated at 37°C for 30 min. Changes in absorbance were measured at 
490 nm using GloMax® Multi Detection System (Sunnyvale, CA, USA).  
For Hek-293T, MCF-7 and MDA-MB-231 cell lines, cell viability was assessed by Prof. 
Lídia Gonçalves using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT), a yellow, water-soluble tetrazolium dye that is converted by mitochondrial 
dehydrogenases in viable cells to a water-insoluble, purple formazan. The procedure is similar 
to the MTS assay. The main difference is that cell media was removed and replaced with 
fresh medium, the MTT dye solution was added to each well (5 mg/mL in 10mM phosphate 
buffer solution at pH 7.4). After an incubation period of 3h the media was removed and 
intracellular formazan crystals were solubilized and extracted with DMSO. After 15 min at 
room temperature absorbance was measured at 570nm in a microplate reader (FLUOstar 
Omega, BMG Labtech, Germany)96. 
Cell viability results for each concentration were normalized regarding the control samples 
and obtained accordingly to the following equation (2): 
 
(2)  
 
General cell death was evaluated using the lactate dehydrogenase (LDH) Cytotoxicity 
Detection KitPLUS (Roche Diagnostics GmbH, Manheim, Germany), according to the 
manufacturer’s instructions. The LDH assay measures membrane integrity as a function of the 
amount of cytoplasmic LDH released into the medium that can be quantified by a coupled 
enzymatic reaction. In the first step, LDH catalyzes the conversion of lactate to pyruvate via 
reduction of NAD+ to NADH. In the second step, diaphorase uses NADH to reduce a 
tetrazolium salt (INT) to a red formazan product. Thus, the level of formazan is directly 
proportional to the amount of LDH released, which is indicative of cytotoxicity. Hence, 50 µL 
of supernatant from treated cells was transferred into a new 96-well plate and then incubated 
with 50 µL of assay substrate for 10 to 30 min, at room temperature, protected from light. 
Scheme 5 - Schematic diagram of compound incubation. 
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Absorbance readings were measured at 490 nm, with 620 nm reference wavelength using a 
Bio-Rad Model 680 microplate reader.  
The percentage of cellular death induced by compounds incubation was determined using 
Excel and a non-linear regression in GraphPad PRISM software. 
 
6.3.3. IC50 determination 
To determine the dose-response curves and the concentration that inhibited cell growth by 
50% (IC50) of the lead compounds, we used GraphPad Prism v.5.00 (GraphPad Software, San 
Diego, CA, USA) with the log (inhibitor) versus response function. In all cases, DMSO was 
used as control. 
 
6.3.4. Evaluation of Apoptosis by Flow Cytometry (Guava Nexin assay) 
Annexin V-FITC (Fluorescein Isothiocyanate) and and 7-Aminoactinomycin D (7-AAD) 
double staining is a common procedure to discriminate viable cells, early apoptotic and late 
apoptotic cells. Loss of plasma membrane asymmetry is one of the earliest features of 
apoptosis. In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is 
translocated from the inner to the outer leaflet of the plasma membrane, thereby exposing PS 
to the external cellular environment. Annexin V is a protein with high affinity for PS, and 
binds to exposed apoptotic cell surface PS. Annexin V can be conjugated to fluorochromes 
while retaining its high affinity for PS and thus serves as a sensitive probe for flow cytometric 
analysis of cells undergoing apoptosis. PS translocation precedes the loss of membrane 
integrity, which accompanies the later stages of cell death. Therefore, staining with Annexin 
V is typically used in conjunction with a vital dye such as and 7-Aminoactinomycin D (7-
AAD) for identification of early and late apoptotic cells. Viable cells with intact membranes 
exclude 7-AAD, whereas the membranes of dead and damaged cells are permeable to 7-
AAD97–99. 
HCT-116 p53(+/+) and MDA-MB-231 cells were plated in 24-well plates at 5x104 and 
2.5x104 cells/well, respectively. Twenty-four hours after plating, cells were exposed to: 1) 
compounds in test at IC50 concentration; 2) compounds in test at 2xIC50 concentration, and 3) 
DMSO (control group), for 72 h. After that, the culture medium was collected and cells 
dettached with Accutase. Cells were collected and centrifuged at 500 g for 5 minutes at 4⁰C. 
The cell pellet was resuspended in PBS/2% FBS. Subsequently, 50 µL of cell suspension 
were mixed with 50 µL of Guava Nexin reagent and incubated for 20 minutes, at room 
temperature in the absence of light. Following the staining procedure, sample acquisition and 
data analysis of at least 5000 events per sample were performed using the Guava easyCyteTM 
Flow Cytometer (Merck Millipore) and Nexin software module.  
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6.3.5. Cell Cycle Analysis 
The effects of compounds on cell cycle progression were verified using a standard 
propidium iodide staining procedure followed by flow cytometry analysis. Propidium iodide 
is a fluorescent intercalating agent that has high affinity to nucleic acids100,101. 
HCT116 p53+/+and MCF-7 cells were plated in 6-well plates at 1.5×105 cells/well. 
Twenty-four hours after plating, cells were treated with the compounds in test at the 
IC50 concentration, or DMSO, for additional 24 or 48 h. After that, cells were detached with 
Tryple reagent and collected by centrifuged at 800 g for 5 min, at 4⁰C. Cell pellets were 
resuspended in cold PBS and added an equal volume of 80% ice-cold ethanol (-20⁰C) drop by 
drop, while vortexing gently. Samples were stored at -4⁰C until data acquisition. For cell 
cycle analysis, cells were centrifuged again at 850g for 5 minutes, at 4⁰C, and cell pellets 
were resuspended in 25μg/mL propidium iodide (PI) (Fluka, Sigma-Aldrich) and 50μg/mL 
RNase A (Sigma-Aldric) and further incubated for 30 min. Sample acquisition and data 
analysis were performed using the Guava easyCyteTM Flow Cytometer (Merck Millipore) and 
Guava analysis software, with the acquisition of at least 10000 events per sample102,103. 
 
6.3.6. Total protein extraction  
HCT-116 p53(+/+) and MDA-MB-231 cells were plated in 60 mm dishes at 8x105 and 5x105 
cells/dish. Twenty-four hours after plating, cells were exposed to the compounds in test at the 
IC50 and 2xIC50 concentration, or vehicle control (DMSO), for additional 72 h. After that, 
floating and adherent cells were collected directly in nonyl phenoxypolyethoxylethanol (NP-
40) lysis buffer (1% NP-40, 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 10% 
Glycerol, 1 mM dithiothreitol (DTT), and 1X proteases and phosphatases inhibitors), 
followed by sonication and centrifugation at 3200 g for 10 min at 4°C. Total protein extracts 
were recovered and stored at - 80 ºC. 
Protein concentration was determined by the colorimetric Bradford method using the Bio-
Rad Protein Assay reagent (Bio-Rad), according to the manufacturer’s instructions. BSA 
(Sigma-Aldrich) was used as standard, and absorbance measurements were performed at 595 
nm using GloMax-Multi+ Detection System (Promega). Protein concentrations were 
interpolated from the BSA standard curve using Excel Software. 
  
6.3.7. Western blot analysis and densitometric analysis 
Steady-state protein production was determined by Western blot analysis. Briefly, total 
protein extracts were separated on 8% and 14% (w/v) sodium dodecyl sulfate (SDS) - 
polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes using the 
Trans-blot Turbo Transfer System (Biorad). Uniform protein loading and transfer was 
confirmed by transient staining with 0.2% Ponceau S (Merck, Darmstadt, Germany). Next, 
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nonspecific binding sites were blocked with a 5% milk solution in Tris-buffered saline (TBS) 
for 1 h.  Membranes were then incubated overnight at 4⁰C with a mouse monoclonal anti-p53 
(Pab-240, sc-99, 1:200), anti-MDM2 (SMP-14, sc-965, 1:200), anti-caspase-3 (H-277, sc-
7148, 1:100) and anti-Parp-1/2 (H-250, sc-7150, 1:2000) (Santa Cruz Biotechnology, Santa 
Cruz, CA). Membranes were then washed three times with TBS containing 0.2% Tween 20 
(TBS-T), and incubated with anti-rabbit or anti-mouse secondary antibodies conjugated with 
horseradish peroxidase (Bio-Rad) for 2 h at room temperature. After rinsing three times with 
TBS-T, the immunoreactive complexes were visualized by chemiluminescence with 
ImmobilonTM Western (Milipore) or SuperSignal West Femto substrate (Thermo Fisher 
Scientific, Inc.). Ponceau was used as loading control. Densitometric analysis was performed 
with the Image Lab software Version 5.1 Beta (Bio-Rad).  
 
6.3.8. Evaluation of caspase-3/7 activity 
Caspase-3 and -7 activities were measured using the Caspase-Glo 3/7 Assay (Promega). 
This assay is based on the cleavage of a pro-luminescent substrate containing the specific 
DEVD sequence recognized by caspase-3 and -7 to release aminoluciferin in cell lysates. The 
subsequent luciferase cleavage of the unconjugated aminoluciferin generates a luminescent 
signal directly proportional to the amount of caspase activity present in the sample. In a 96-
well plate were incubated 15µg of total protein extracts from HCT-116 and MDA-MB-231 
cells, in 50µL of total volume and 50µL of caspase-Glo 3/7 reagent. Subsequently the mixture 
was incubated at room temperature for 30 min, leading to stabilization of substrate cleavage 
by caspases, and accumulation of luminescent signal104,105. The resulting luminescence was 
measured using the GloMax-Multi+ Detection System (Promega). 
The data were analyzed using Excel and GraphPad PRISM software. 
 
6.3.9. Combined Therapy Strategies 
The objective of drug combination therapies is to achieve improved therapeutic results. 
In this project, the commercial chemotherapeutic drug used is described in Table 9 and it 
was kindly provided by the laboratory of Prof. Cecilia Rodrigues in collaboration with the 
hospital pharmacy of Hospital Santa Maria in Lisboa. 
 
Table 7 - Main feature of commercial chemotherapeutic drug used in the course of this project described as drug 
denomination, molecular weight, solvent, manufacturing company and molecular target. 
Drug Denomination Molecular weight (gmol-1) Solvent 
Manufacturing 
company Molecular target 
5-Fluorouracil 130.08 PBS Accord Inhibitor of thymidylate 
synthetase88,89 
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6.3.9.1. Cytotoxic potential evaluation 
HCT116 p53(+/+) cells were plated as mentioned above. However, instead of incubating 
cells with compounds at IC50 concentration for 72 hours, the following combined strategies 
were applied: 
 
 
 
 
 
 
 
Where A is the spiropyrazoline oxindole compound tested and B is the commercial drug. 
The strategy combines both A and B drugs at appropriate concentrations. In the control 
groups equivalent amounts of DMSO were added. 
The data were analyzed using Excel and GraphPad PRISM software using the following 
equation: 
 
(3) 
 
 
Where CDI is coefficient drug interaction, AB is the cell viability ratio of combinatory 
strategy, A is the cell viability ratio of single agent A and B is the cell viability ratio of single 
agent B. Coefficient drug interaction (CDI) is a tool to analyze interaction between drugs 
allowing distinguishing synergistic, additive and antagonistic effects. For CDI values < 1, 
drugs have a synergistic effect, for CDI = 1, drugs have an additive effect and for CDI values 
> 1, drugs have an antagonistic effect86,106–115. 
 
6.3.10. Bimolecular Fluorescence Complementation (BiFC) Assay 
To evaluate p53-MDM2 protein-protein interaction, HCT116 p53(-/-) cells were co-
transfected using 1 µg of each BiFC pair plasmid and Lipofectamine 2000 (Invitrogen), 
following the manufacturer’s instructions. 4–6 h after transfection, the medium was replaced 
with fresh medium, and the compounds in test were added to a final concentration of 5μM, 
Assay for 
viable cells Cell seeding 
Compound A 
+ 
Compound B  
Record 
Data 
24 hours 72 hours 30 minutes 
Plating Exposure MTS 
Scheme 6 - Cytotoxic potential evaluation. The cells per well were seeded in 96-well plate at 37ºC, humidified 
atmosphere of 99% and 5% (v/v) CO2, and 24 hours later the cells were exposed to compounds A and B for 
more 72 hours in the same conditions. Then, each well was aspirated and 100 μL of a solution mixture of 
complete culture medium, MTS and PMS (100:19:1) were pipetted to each well. After 30 minutes of incubation 
the absorbance at 490nm was read in a microplate reader. 
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10μM and 20μM. Nutlin-3 at the same concentrations was used as positive control. Equal 
amounts of vehicle (DMSO) were used as control. Cells were washed twice with Ca2+ and 
Mg2+ free PBS (Invitrogen Corp.), treated with accutase and harvested with culture medium. 
Cell suspensions were centrifuged, supernatants discarded, and cell pellets resuspended in 
PBS. Fluorescence was measured using a Guava easyCyte™ Flow Cytometer71,90. 
 
6.3.11. Statistical analysis 
Data were analyzed statistically using the GraphPad software. All data are presented as mean 
± standard error of the mean (SEM) or mean ± standard deviation (SD) of at least three 
independent experiments. Differences between means were tested for significance using the 
Student's t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Errata da Dissertação: The therapeutic potential of small molecules p53-MDM
protein-protein interaction inhibitors
Na pdgina 24 onde se 18: “As p53 tumour” deve ler-se: “p53 tumour”.
Na página 27 onde se 18: “activation (Figure 4).” deve Icr-se: “activation (Figure 3).”.
Na página 37, em Scheme 3 onde se 18: “Synthesis of hydrazonoyl 7 and hydrazonyl
chlorides 4.” deve ler-se: “Synthesis of hydrazonoyl 7 and hydrazonyl chlorides 4. (a)
aqueous ethanol 20%, r.t., 2-3h, 81-99%; (b) NCS. S(CH3)2, 0°C, 15 mm; -78°C, lh, then
allowed to warm up to r.t., 62-88%.”,
Na página 41 onde se 18: “Si
— (...) ratio MDA-MB-231 IC5JMCF-7 IC50.” deve ler-se:
“Ia] IC50 determined by the MTF method after 48h compound incubation. Each value is the
mean (1C50 ± SD) of three independent experiments; [b] IC50 determined by the MTS method
after 72h compound incubation, Each value is the mean (IC50 ± SD) of three independent
experiments performed in duplicate. (...) Si — (...) ratio MDA-MB-23 1 1C5JMCF-7 IC50.”
Na pdgina 43, na Figure 9 onde se 16: “C..) fibroblasts (CCD-lOco) following 72 h
incubation ith compounds” deve Icr-se: “C..) fibroblasts (CCD-l8co) following 72 h
compound incubation”.
Na página 48, na Figure 14 onde se 18: “Threshold- CDI value threshold (CDI=1 ).“ deve
Icr-se: “Threshold- CDI value threshold (CDI=1). 2eIC10=9.5pM; 2elC20=10.7pM;
ZeICso=l3.OpM and 5-FUIC10=1 7pM; 5-FUIC20=2.2pM; 5-FU1C50=3.2pM.”.
Na página 52 onde se 18: Table 5” deve ler-se: “Table 7”.
Na pdgina 53 onde se 18: “and growth arrest (...) expression levels.” deve 1cr-se: “and cell
cycle arrest (...) expression levels in HCT-l I 6p53” cell line.”.
Na página 59 onde se 18: “Figure 22- fibroblasts (CCD-IOco)” deve Icr-se: “Figure 23 —
fibroblasts (CCD-l 8co)”, e onde se 18: “Figure 23” deve ler-se: “Figure 24”.
Na página 60 onde se 18: “Figure 24” deve Icr-se: “Figure 25”.
Na página 61 onde se 18: “G2IM and a dose dependent increase” deve ler-se: “G2/M and a
significant increase”.
Na página 63 onde se 18: “Compounds 2a, 2e, 2g, 21. 2j, 21 and 2m” deve Icr-se:
“Compounds 2b, 2e, 2g, 2i, 2j, 2), 2m and 2q”.
Na página 65 onde se 18: “the MDM2-p53 interaction” deve Icr-se: “the p53-MDM2
interaction” e onde se 16: “MDM2 expression levels.” Deve Icr-se: “MDM2 expression levels
in HCT-I 1651’tt cell line.”
Nas páginas 69 a80 especificou-se o tipo debase utilizada pan cada composto sintetizado,
e onde se 16: “CDCI3” deve ler-se: “CDCI3”.
Na página 88 deve Icr-se: 6.3.1l.Statistical analysis - Data were analyzed statistically using the
GraphPad software. All data are presented as mean ± standard entr of the mean (SEM) or mean ±
standard deviation (SD) of independent experiments. Differences between means were tested for
significance using the Student’s t-test (tp <0.05; *‘Kp <0.01; ***p <0.001).
1
